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This study investigated the influence of the addition of Magnesium Stearate (MgSt) with 
commercial grade (Lactochem®) and smoothed carrier lactose particles (Nanolac®) on the 
performance of a budesonide-lactose dry powder inhaler (DPI) formulation. A Multi Stage 
Liquid Impinger (MSLI) was used to investigate the in vitro deposition profile of the 
budesonide-lactose formulations containing different concentrations of Magnesium 
Stearate (MgSt), a widely used lubricant in the manufacture of pharmaceutical solid 
dosage forms. Upon pre-blending Magnesium Stearate using high shear blending process 
the aerosolisation performance of the DPI generally increased. This study suggested that 
the addition of 0.25% w/w MgSt in the formulation with Lactochem (63-90 m sieved 
lactose) resulted in the greatest aerosolisation efficiency amongst the other Lactochem 
formulations, while for the Nanolac formulations the addition of 0.5% w/w MgSt resulted 
in the most efficient aerosolisation. This difference could be attributed to the different 
surface morphology between the two carriers used and therefore the difference in their 
interparticulate forces between the drug particles and the surface of the carrier. 
The study suggested that an optimum concentration of the MgSt needs to be reached in 
order to get balanced interparticulate forces between the drug particles and the carrier 
surface which will enable maximum aerosolisation deposition. The influence of storage 
humidity on the aerosolisation efficiency and therefore the adhesion properties of the 
same formulations were also investigated. The formulations were stored for 3 months at 
25°C, 75%RH and 40°C, 75%RH. Storage humidity had a significant effect on the 
aerosolisation efficiency of all formulations except from the formulation containing 0.5% 
w/w MgSt. This could be due to the formation of a hydrophobic layer on the surface of the 
powder formulation, making it less sensitive to moisture. In addition, at high humidity, 
surface amorphous regions may have the ability to re-crystallize and effectively fuse to the 
lactose carrier surface, reducing the ability for the powder to be aerosolized and 
decreasing the FPF. This study suggests therefore, that an optimum concentration of the 
MgSt needs to be reached in order not only increase aerolisation efficiency but to maintain 
formulation stability upon exposure to elevated conditions of temperature and relative 
humidity. 
 ii
The use of a novel optical technology, the VariDose, was also investigated in order to 
obtain a system which can lead to an effective and efficient system for testing aerosol 
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1.1 General introduction 
 
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and 
cystic fibrosis have increased dramatically over the last decade. The increase need to 
develop novel ways of administering inhaled drugs has led to increasing attention to the 
field of pulmonary delivery.  Pulmonary drug delivery is an attractive route of 
administering drugs to the lungs since it is non-invasive and thus increases patient 
acceptance and compliance. In addition, relative small doses are required (compared to oral 
or parenteral administration), minimises side effects and the drug action onset is rapid since 
the drug is delivered directly to the target thereby reducing systemic exposure. 
 
Furthermore, delivery via the inhalation route provides a portal entry for systemically 
acting drugs, since it offers a large absorptive surface area for the rapid drug absorption in 
the peripheral airways1.  The first drug to be delivered via the lungs was ergotamine for the 
treatment of migraine in the 1960’s. More recently, the first inhalable formulation of 
insulin was approved for use in Europe and the United States2.  
 
One of the major issues with the drug delivery via inhalation, however, is in the 
inefficiency of the drug delivery systems particularly with issues relating to device related 
losses, large deposition of the therapeutic dose in the mouth and throat by inertia and rapid 
particle removal from the lungs by various clearance mechanisms. However, these 
problems may be addressed by modifying the different factors that influence drug 
deposition, such as physico-chemical properties of the drug formulation (particle size and 
shape), its delivery characteristics (aerodynamic diameter), charge, density, hygroscopicity 
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etc. Furthermore, new inhaler devices are continually being developed to increase 
deaggregation efficiency.  
 
There are currently three major drug delivery systems: pressurized metered-dose  
inhalers (pMDIs), dry powder inhalers (DPIs) and nebulisers. These types of systems  
have been extensively investigated and undergone significant technological advancements 
in terms of their engineering and in the preparation of their respective formulations.  
 
1.1.1 Respiratory tract delivery 
 
The primary function of the respiratory system is to supply a rich supply of oxygen to the 
blood which is delivered to all the organs, muscles etc. of the body. It achieves this by a 
respiratory breathing cycle. During an inhalation/exhalation cycle, an exchange in gases 
occurs; oxygen is being inhaled and supplied to the heart via the peripheral airways and 
carbon dioxide is subsequently exhaled. In humans, it is the main two bronchi (produced by 
the bifurcation of the trachea) that enter the roots of the lungs. The bronchi continue to 
divide within the lung and after multiple divisions give rise to bronchioles. The bronchial 
tree continues branching until it reaches the level of terminal bronchioles which lead to the 
alveolar sacs. Human lungs are located in two cavities and are separated into lobes with 
three lobes on the right and two on the left3. 
The respiratory tract is divided into three regions: 1) the upper respiratory tract which  
includes the nose and nasal passages, the paranasal sinuses and throat or pharynx, 2) the  
respiratory, or conducting, airways which includes the trachea, bronchi and bronchioles and  
3) the peripheral airways, which includes the respiratory bronchiole, the alveolar ducts, the  
alveolar sacs and the alveoli. In addition to the main function of the transport of oxygen 
into and carbon dioxide out of the body, the respiratory tract has also evolved into a very 
effective filter of airborne materials, particularly as it comes into contact with the 
environment and is exposed to micro organisms in the air. In addition, it is also exposed to 
many potential pathogens via dust and smoke which are inhaled from the air4. In most 
cases, asthma is caused by inhaling an allergen that sets off the chain of biochemical and 
tissue changes leading to inflammation of the smooth muscle of the airways and 
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bronchoconstriction3.  A schematic diagram of the branching airways of the human 
respiratory tract is shown in figure 1.1.  
 
                  
                           
 
           Figure 1.1 Diagrammatic representation of the structure of a human lung 
                               (Copyright © 1996 Johns Hopkins University)  
 
 
 1.1.2 Particle deposition in the lungs 
 
The deposition of inhaled drug aerosol in the respiratory system is influenced by many  
factors such as inertial impaction, gravitational sedimentation, Brownian diffusion,  
interception and electrostatic forces5. The degree of lung deposition is strongly affected by 
the aerodynamic diameter of the particles and their distribution. Aerodynamic particle size 
is the most important physicochemical parameter influencing deposition in the lung. The 
optimum size range of particulates for inhalation therapy has been shown to be between 1 
and 5μm depending on the desired target site6.  
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The aerodynamic particle size influences where in the respiratory tract the aerosol particles  
will be deposited.  Particles with an aerodynamic diameter (dae) larger than 6 μm deposit 
mainly in the oropharyngeal region, particles with a dae between 4 and 6 μm deposit in the 
conducting airways (e.g bronchioles), while particles with dae less than 2μm deposit in the 
peripheral regions of the lung (e.g. alveoli).  
 
Aerosols come in a variety of shapes and sizes therefore different particles characteristics 
will be affected by different particle deposition mechanisms. This effect is taken into 
account by determining their aerodynamic particle diameter of the aerosol particles. The 
main mechanisms of particle removal from an inhaled dose are summarised below: 
 
1.1.2.1 Inertial Impaction 
 
Large particles (dae>6μm) are affected by inertial impaction when the gas air stream is fast,  
changing direction or turbulent7. The impaction is caused by the inertial properties of the 
particles, which tends to resist a change in the direction of its path. Thus, particles of a 
certain mass travelling in an air stream at a sufficient velocity will not lose momentum 
sufficiently quickly to be able to relax into a new direction of the airflow and so will impact 
in the upper airways. Inertial impaction is the main mode of particle removal in 
oropharynx, larynx and at bifurcations in the upper airways7. 
 
1.1.2.2 Gravitational Sedimentation 
 
When the air velocity in respiratory tract is low and the residence time is high, particles are  
affected by gravitational sedimentation. It is dependant on the terminal settling velocity of  
the particle and is an important deposition in the bronchioles, where residence time is high  
and velocity is low. This process is time dependant, as particles must have sufficient 





1.1.2.3 Brownian Diffusion 
 
Small particles (dae<0.1μm) are affected by Brownian diffusion, which is caused when  
particles are randomly bombarded by air molecules giving rise to a “random walk.”  
Brownian motion results in particles following a random and variable path and for the  
particles <0.5μm in diameter it will tend to cause greater displacement than sedimentation  
and so the primary mechanism of deposition in the terminal bronchioles and alveolar  
regions7. 
 
1.1.2.4 Interception and Electrostatic Deposition 
 
Other particle deposition mechanisms include interception where particles travelling  
within the air stream are intercepted by contact with the respiratory airway and electrostatic  
deposition where deposition where highly charged particles may be efficiently deposited if  
the electric field induced by an image charge on the airways is sufficient to direct the  
aerosol particles towards the airway walls 7. 
 
 
1.1.3 Drug delivery systems 
 
Pressurised metered dose inhalers have been the system of choice for delivery of  
inhaled therapies for airway diseases for decades, but recent environmental concerns over  
the use of chlorofluorocarbon (CFC) propellants, which have been directly linked  
to the depletion of the ozone layer, has forced the pharmaceutical industry to re-address 
their long term use. Following the Montreal protocol in 1987, the use of CFC driven 
aerosols, have been phased out, although an extension was provided for inhaler devices 
until an alternative formulation could be obtained8. This led to the reformulation of pMDIs 
using hydrofluoroalkanes (HFAs) as alternative propellants.  
 
Formulation of the active pharmaceutical ingredients in these propellants have been fraught 
with difficulties particularly because of crucial differences in densities and solubilities of 
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drugs and excipients9. As a result of the significant issues in formulating new chemical 
entities as pMDI formulations, several of the major pharmaceutical companies have 
favoured their development of new inhalation products away from the pMDI platform8. In 
pMDIs, a high vapour pressure gas, typically a liquid propellant (CFC) and a solution or 
suspension of fine drug particles is contained within a pressurised canister10. Actuation of 
an inhaler valve results in the release of a metered volume of this solution or suspension 
which is driven at high speed through a narrow orifice by the volatile expansion of the 
pressurised liquid, resulting in the delivery of the dose to the respiratory tract 10. 
 
Nebulisers provide a means of delivering high doses of a drug directly to the lungs7 and are 
usually prescribed to people with severe, life-threatening asthma or COPD. A compressor is 
traditionally used to provide sufficient energy to a solution to make a fine mist of the solute 
material. The mist is being continually aerolised via the nebuliser which allows the patient 
to continually inhale the aerosol without the requirements for device-patient co-ordination 
with pMDI devices and the forced inhalation breathing manoeuvre required for passive DPI 
devices.  
 
The aerosol droplets produced have typically a smaller aerodynamic particle size than  
DPIs and pMDIs, making them capable of penetrating the deeper regions of the airways.  
However, the use of nebulisers is limited due to the length of time needed to deliver the  
required dose (usually 10 to 15 minutes), they are not portable and the nebuliser are  
costly7,11. 
 
The problems and limitations with nebulisers and pMDIs has led to the increasing  
development and acceptability of the use of Dry powder inhalers (DPIs) for the delivery 
of therapeutic agents to the respiratory tract. 
 
The use of DPIs for inhalation therapy for obstructive airway disease management such as 
asthma and chronic obstructive airway disease (COPD) has gained significant popularity  
during the early part of the 21st century12. DPIs were firstly used in the treatment of asthma  
in the 1960’s and the 1970’s, for the delivery of high powder loads. The first marketed  
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passive unit-dose DPI device was the Fisons Intal Spinhaler device for the delivery of 
sodium cromoglycolate. This was soon followed by the development of the Glaxo  
Rotahaler device for the delivery of the β2-agonist salbutamol sulphate.13 
 
DPI formulations typically involve a blend of the drug particles (<5μm) and coarse  
excipient particles (63-90µm).Drug particulates are blended with the inert crystalline carrier  
materials to reduce the cohesive interactions between the primary drug particles and to  
improve formulation flowability for device filling and subsequently the fludisation of the  
formulation during device activation 14. Carrier based systems also allow accurate metering 
of very small quantities of potent drug (>6 μg). 
 
The blend forms an ordered mixture of the drug and excipient 15 and is typically referred to 
as a binary or carrier-based DPI formulation. The most commonly used carrier in DPI 
formulations is α-lactose-monohydrate which is relatively cheap and pharmacologically 
inert16. During a forced inhalation manoeuvre, the resistance to the air flow generated via 
the passive DPI device may generate sufficient drag and shear forces to overcome the 
interparticulate attractive force between the drug particles and carrier particle surface 
leading to the re-suspension of the drug particles for lung delivery17. If the drug particles 
are strongly adhering to the lactose surface the aerodynamic forces generated within the 
DPI device may not be sufficient for efficient drug re-suspension leading to a low fine 
particle dose delivery. The larger carrier particles and the drug particles which have not 
been re-suspended during aerolisation impact in the oropharynx and the upper airways and 
eventually are swallowed14. 
This process of aerolisation is key to understanding the performance (how much drug 
reaches the target site of action) of the formulation and is dependant upon a fine balance of  
the adhesive and cohesive forces between the drug and carrier particles 18,19. The adhesive  
forces between the drug and carrier particles are known to be dependant upon many factors  
such as size, shape, surface roughness and morphology of the particles, the presence of  
electrostatic charging, the environmental conditions (relative humidity and temperature)  
and the process (e.g. low shear versus high shear processing) by which the blend is  
formed16,19,20. 
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To achieve the optimum particle size distribution of the drug particles for inhalation  
therapy, energy intensive comminution techniques (e.g. air-jet milling) are commonly  
used. However, these micronised powders, have a high bulk volume and exhibit very poor 
flow characteristics due to the highly cohesive interactive forces between particles, making 
them difficult to handle and process. This problem is effectively overcome by the use of  
carriers, as mentioned above21. 
 
The deposition of inhaled drug aerosol in the respiratory system is also influenced by the  
variability of the energy source (i.e. the patient) and their inhalation technique, the device  
used, the drug substance and the formulation. The performance of a DPI is a direct function 
of the energy supplied by the forced inhalation breath of patients to de-aggregate and 
deliver the active ingredient to the site of action6. 
 
There are three primary forces in a dry powder inhalation system which influence the total  
adhesion and cohesion of the system. These are van der Waals forces, electrostatic and  
capillary interactions and their characteristics such as magnitude, total interaction and  
subsequent aerolization efficiency which will depend on the physicochemical  
characteristics of the drug and the carrier, and the environmental conditions in which they  
are stored and delivered, ie humidity, temperature12. 
 
The engineering of the DPI devices are designed to provide sufficient resistance to the 
inspiration and the inspiratory flow of the patient to induce the energy required for de-
aggregation and aerosolisation of the medication. High resistance devices, such as the 
reservoir based Clickhaler, require a considerable inspiratory flow to produce a dose and 
provides effective drug delivery to the lower respiratory tract22. The main problem with the 
majority of marketed DPIs is in the variability of the source (i.e. the patient) and its 
dependence on the inspiratory flow to deliver the payload. Patients, in particular the elderly 
people and/or children, cannot provide sufficient inspiratory flow for efficient drug re-




1.2 Interparticulate interactions 
 
In order to increase the degree of particle de-aggregation there is a need to understand the  
physical forces which may directly influence the particulate interactions within a 
formulation and the requirements for overcoming the forces to effectively de-aggregate the  
particles. The interparticulate interactions are one of the most important factors in 
determining the performance and behaviour of carrier-based DPI formulations. 
 
Particle interactions are primarily dictated by van der Waals forces, electrostatic forces and  
capillary forces. The effect of these three forces to the total interaction have been shown to  
be dependant on the physicochemical properties of the materials and environmental  
conditions such as temperature and humidity. The effect of the environmental conditions on  
the interparticulate forces and therefore aerosolization performance, will be drug specific  
signifying that a detailed understanding of the DPI and its properties are required for   
formulation development. 
 
1.2.1 Electrostatic forces 
 
One of the major problems associated with the DPIs is the generation of electrostatic  
charges, which have been shown to influence the performance of the inhaler device23. 
Electrostatic charges are generated when two different materials are brought together and  
then separated23. Such a charge build-up develops an electric field that has an effect on  
other subjects at a distance.  
 
During aerosolisation processes like shaking, priming, metering and dispersion, the  
movement of particles and droplets with the surface of the inhaler device provides the ideal  
conditions for the development of charge by triboelectrification24.  
Triboelectrification is whereby an electrostatic charge is generated by the contact and  
separation of two dissimilar materials, resulting in oppositely charged surfaces24.     
Electrostatic effects were first reported almost 2500 years ago but it was only in 1780’s  
when Coulomb described the electrostatic force: 
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Equation 1.1                                   2
2
d
CqF =                                                        
 
This equation shows that the force (F) between two materials carrying a charge (q) is  
inversely proportional to the square of the distance (d) between the materials and C is  
constant7. In the simplest case of two point electric charges, the magnitude of the 
electrostatic force, Fel, between them can be described by Coulomb’s law: 
                                             







el επε=             
 
 
Where Fel : the force of attraction or repulsion (N) 
           q1: electric charge on the first particle in Coulomb (q) 
           q2: electric charge on the second particle in Coulomb (q) 
           4π: constant of proportionality  
           ε0: permittivity of free space (Fm-1) 
           d: distance between the charge points in meters (m) 
 
For a single charged particle near a flat (plane) conducting surface the relationship 
becomes: 
  




qFel πε=                                                     
 
Equation 1.3 shows that a charged particle will always be attracted to an uncharged  
conducting surface7.  
 
1.2.2 Effect of humidity on electrostatic forces 
 
At low relative humidity, electrostatic forces predominate in particle interactions. As  
previously stated, the multiple contacts between drug particles and surfaces during handling  
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and aerosolization will lead to triboelectric charging. These charges lead to an increase in 
the attractive forces between the micronized materials, resulting in an increase in the 
contact area and therefore causing a greater degree of cohesion. However, in the presence 
of moist air, water can adsorb onto the surface of the material, allowing mobilization of 
electrons, increasing surface conductivity and subsequently reducing specific charge25. 
 
1.2.3 van der Waals forces 
 
The van der Waals force is the fundamental quantum mechanical inter-molecular force that  
results when molecules come very close to one another. It is a finite attractive force which  
is present between all atoms and is short range force26. The adhesive van der Waals force 
(Fvdw) between a spherical particle and a plane surface is determined by the following 
equation: 
 
         Equation 1.4                                      
26r
AdFvdw =                                                         
Where d: diameter of particle 
            r: distance between particle and plane surface 
           A: Hamaker constant which represents the interaction energy that is   
               dependant on the molecular properties of both interacting materials 
 
         Equation 1.5             Where:        A= π2 ν1ν2λd1,2 
 
Where ν1 & ν2: number of atoms per unit volume of particles1 and 2 
              λd1,2: constant of dispersion 
 
        Equation 1.6             Where:          λd1,2 = -3/4 hfa2 
 
Where h: Planck’s constant 
            f: vibration frequency of the interacting electronic oscillators 
            α: polarisability of the molecules 
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The van der Waals force between two ideally smooth spherical particles in vacuum is  
expressed by the equation: 
 









AFvdw                                      
 
As can be seen from both equations, the separation distance (r) of the interacting materials  
is a critical parameter7. 
 
 1.2.3.1 Casimir-orientation van der Waals forces 
These forces arise between two polar molecules each of which has the electric dipole  
moment. 
 
1.2.3.2 Debye-induction van der Waals forces 
These forces arise between polar and non polar molecules. 
 
1.2.3.3 Dispersive or London van der Waals forces  
These are weak intermolecular forces that arise from the attractive force between transient  
dipoles in molecules without permanent multiple moments. These forces are finite between  
all atoms and are of predominant importance between macroscopic bodies. They are the  
most ubiquitous of the van der Waals forces. 
 
1.2.4 Effect of humidity on van der Waals forces 
 
The presence of moisture increases the van der Waals forces as a decrease of the  
interparticle distance will occur due to the fact that the adsorbed layers may be considered  





1.2.5 Capillary forces 
 
Capillary forces result from trapped liquid that produce an attractive force due to Laplace  
pressure differences and surface tension forces. If the condensation of the water vapour is  
significant, usually at high relative humidities, the formation of a liquid bridge may arise  
between two conducting surfaces due to capillary interaction, leading to the formation of  
the force. In addition, this structure leads to an increased force of adhesion between the  
particles due to the surface tension of water. At high humidities, (above 65%), capillary  
forces become the dominant force responsible for adhesion7. 
 
The magnitude of the capillary force (FC) between two identical smooth spheres (radius r)  
may be simply calculated as: 
 
               Equation 1.8                         FC = 2πγLrcosα 
 
Where: γL is the surface tension of water 
             α is the contact angle between water and the spheres 
 
The capillary force resulting from the condensation of water in the interface in the case of a  
sphere (radius r) is calculated by: 
 
                Equation 1.9                         FC = 2πγLr(cos α+cos β) 
 
The formation of capillary forces by condensation leads to undesirable events such as  
an increase in the strength of granules, which leads to flow problems and/or caking of  
powder samples during storage and handling. The prediction and control of the magnitude  
of capillary forces is necessary for eliminating or minimizing these undesirable events. In  
addition, volume reduction with evaporation of the liquid can produce sufficient strength to  
collapse fragile suspended structures, resulting in the damage of the devices and the  
promotion of the adhesion that results from van der Waals and electrostatic forces7.  
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1.2.5 Effect of humidity on capillary forces 
 
At high relative humidity, capillary forces predominate in particle interactions. The 
presence of water on the surface of the powders causes attractive forces due to the capillary 
action of adsorbed water layers. At high humidities, water vapour can condense in the 
capillaries which are present between individual powder particles forming liquid bridges. 
The presence of these liquid bridges increases the cohesive forces between particles leading 
in an increase in tensile strength. In addition, in extreme cases, where the materials are 
highly hydrophilic and hygroscopic, deliquescence and subsequent solidification of the 
particle surfaces could potentially lead to the formation of solid-liquid bridges, therefore 
increasing the particle size and decreasing the fine particle fraction25. 
 
1.3 Factors affecting interparticulate factors 
 
The interparticulate forces are influenced by many factors such as the particle size,  
shape, surface roughness of the particles, surface free energy and relative  
humidity. Each of these factors will be described in detail below.  
 
1.3.1 Particle size 
 
Of all the physical parameters that influence the delivery of dry powder inhaler 
formulations to the lung, the most critical one is the particle aerodynamic diameter. As 
mentioned previously in 1.1.2 section, only particles within the narrow size range of 0.5 to 
5μm can reach the deep lung and avoid impaction in the upper airways. In some cases, if 
the dry powder particles adsorb moisture, they grow in the presence of a humid 
environment or even agglomerate, therefore getting deposited to a different location  
in the respiratory tract and affecting the efficacy of the formulation. Furthermore, larger  
particles tend to be highly adhesive/cohesive and are influenced by particle interactions.  
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The van der Waals, capillary and electrostatic forces all increase with increasing particle 
size. 
  
As particle size decreases, the adhesion forces experienced by a particle become more and  
more significant when compared to the gravitational forces to which it is exposed51. The 
cohesive and adhesive properties of particles with a diameter less than 10 μm are governed 
by the van der Waals forces and the relative influence of the dynamic capillary and 
electrostatic forces. 
 
1.3.2 Particle shape 
 
Particle shape is one of the most uncontrollable factors which may influence 
interparticulate interactions, due to the fact that the methods used to produce particles give  
rise to particles with various geometrical parameters. The van der Waals and electrostatic 
forces both decrease as a function of the square of the separation distance between 
particles. Thus, any effect on particle shape, will therefore have a significant effect on  
interparticulate forces. 
 
1.3.3 Surface roughness of particles 
 
Particle roughness is another important factor that affects the interparticulate forces by  
determining the level of adhesion to other active particles, excipients and inhaler device  
surfaces, via its effect on contact area21. Smoother particles are likely to reduce particle self- 
adhesion, therefore reducing agglomerate formation21. When the particle surfaces are rough,  
the force of adhesion between the drug particles and the carrier surface is low due to the  
small surface contact area and therefore a reduced amount of force is required to  
detach the drug particles from the carrier surface. A perfect sphere sitting on top of a  
perfectly flat surface will have the maximum contact area. Microscopic asperities on 
particle surfaces would dramatically decrease the effective contact area of contiguous 
surfaces, resulting in a concomitant reduction in particle interactions.   
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1.3.4 Surface free energy 
 
The surface free energy of a solid material can be defined as the free energy change during 
the formation of a surface by one unit area in vacuo and is analogous to the surface tension  
of a liquid52,53.  The amount of work required to separate two surfaces is termed the work of 
adhesion (Wa) and is related to the surface free energy of the surfaces by the following 
equation: 
   
  Equation 1.10                                     Wa = A (γ1+ γ2- γ12)                                     
 
Where A: is the area of surface produced by separation 
            γ1 and γ2: are the surface free energy of the 2 surfaces 
            γ12: is the free energy of the 1-2 interface per unit area 
 
The work of cohesion (Wc), which is the work required to separate two surfaces of the  
same material is given by the equation: 
 
Equation 1.11                                Wc = 2A γ1  
 
In general, solids exhibiting high surface energy are more likely to form strong inter- 
surface forces. Therefore, the adhesion and cohesion of respirable drug particles will be 
affected by the surface free energies of the interacting particles7.  
 
1.3.5 Relative humidity 
 
In order to get drug delivery into the lungs from a DPI formulation, the drug particles  
have to detach from the carrier particle surface and penetrate into the lungs. The key factors  
affecting the de-agglomeration and aerosolisation of respirable particles are the  
interparticulate forces between contiguous particle surfaces and the physicochemical  
stability of DPI formulations upon storing and handling at variable environmental  
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conditions of temperature and relative humidity.  
 
DPIs are particularly susceptible to interparticulate forces because micronized powders  
have a high specific surface area. Interparticulate forces are affected by relative humidity 
via two mechanisms. Firstly, the presence of humidity allows the dissipation of electrostatic 
charge from particles, by increasing the conductivity of both the atmosphere and the 
materials themselves, thus decreasing the electrostatic forces7. In addition, relative humidity 
changes induce changes in water activity; at high RH water can condensate at the contact 
points between particles leading to the formation of liquid bridges and an increase in 
capillary forces7. 
 
1.3.5.1 Effect of storage and exposure to a high relative humidity 
 
The interparticulate interactions in adhesive mixtures may change with time, depending on 
the storage conditions. Braun et al (1996) 54 showed that two formulations with different 
strengths of disodium cromoglycate had higher fine particle fractions when stored for 27 
days at 33%RH than the formulations which were stored at 55%RH. In addition, it has also 
been found that the relative humidity of the air during inhalation may influence the fraction 
of the drug detached from the carrier surface54. This can be explained by the fact that 




1.4 Novel developments in improving aerosol delivery performance 
 
Numerous techniques have been applied in modifying the interparticulate interactions in  
DPI formulations and thereby increasing aerosolisation performance. The majority have  
targeted the physical properties of the carrier such as the particle size, shape and surface  
roughness. Other techniques applied include engineering drug particles to produce more  
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uniform drug particulates, using methods such as spray drying and supercritcal fluids. 
Addition of a wetting agent or an anti-adherent material to improve the dispersibility of the 
formulation has been investigated27,28. 
 
In addition, it has been reported that the co-processing of the carrier particles with low  
surface free energy materials like magnesium stearate, leucine, lecithin, increases the  
aerosolisation efficiencies of dry powder inhaler formulations29, by decreasing the drug-
excipient adhesion and thus facilitating the drug detachment upon device actuation. The 
increase in performance is achieved by the anti-adherent and/or anti-friction properties of 
these force control agents (FCAs). 
 
1.4.1 Addition of Magnesium Stearate to DPI formulations 
 
Magnesium stearate is the most widely used lubricant in the manufacture of pharmaceutical  
solid dosage forms30.The structure of magnesium stearate is shown in figure 1.2. 
 
      Molecular formula: C36H70MgO4 
 
Figure 1.2 Chemical structure of Magnesium stearate   
 
During powder formulation, various adjuvants are added to the formulations to form a bulk 
mixture in achieving uniform mixing and flow of the powders in capsules or tablets31. The 
adjuvants influence the physical properties of the tablets; the crushing strength of the tablet 
decreases and the disintegration time increases32. Lubrication involves adding small 
quantities of an antifriction agent to powders or granules and mixing them for a specified 
time31. In general, a lubricant is used to eliminate adherence of the tablet compact to the die, 
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and minimise sticking and picking of the punch face surfaces in contact with the 
compressed tablet31. 
 
As mentioned, MgSt is an effective lubricant, anti-adherent and glidant33and is a  
critical excipient for processing tablets34. MgSt has also been proven to be a functional 
excipient in dry powder inhaler formulations for inhalation. Studies have shown that the 
addition of MgSt improves the powder flow of carrier based ordered mixtures, promotes the 
release and dispersion of the drug particles from the carrier surface and manipulates and 
modifies the interparticulate forces within a DPI formulation30. In addition, it has also been 
shown that MgSt improves the moisture resistance of DPI formulations under high 
humidity conditions30.  
 
In contrast, MgSt is commonly known to cause de-stabilization of ordered powder mixtures 
if not carefully controlled. Furthermore, due to the variability in source, its lubricant 
properties may vary from batch to batch due to the fact that it primarily consists of a 
mixture of magnesium stearate, magnesium palmitate in various proportions together with 
very small amounts of magnesium laurate and myristate35. 
 
As shown for conventional solid dosage forms, the process of blending and the time of  
introduction of MgSt is quite critical to the performance of the  formulation. The duration  
of mixing in the lubricant component affects the properties of the compact as well as the  
properties of the blended mixture by changing the apparent bulk volume, the compression  
force required to make a prescribed compact and the hydrophobic character of the  
mixture31.  
 
It is suggested that after a mixing time of 1 min there is a good correlation between the  
lubricant surface area and the coverage of the base of the material. The distribution of MgSt  
in a powder mass upon mixing is shown in Figure 1.3, below36.                                             
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Figure 1.3 Schematic representation of the distribution of lubricant within a formulation  
 
When MgSt is used within a powder blend, it is either distributed as a free fraction and 
loose agglomerates or it gets deposited as a surface film on the base material. If the mixing 
time is prolonged, then more lubricant will be transferred from the free fraction to the 
surface film and would therefore affect the lubricating properties of the MgSt since both 
free fraction and surface film is required in order to form the die wall36. 
 
The mechanism of lubrication for MgSt involves covering the surface through physical 
mixing upon the initial mixing and the subsequent forming of a film if there is sufficient 
shear. As the mixing continues, the shear effects continue to cause delamination or 
deagglomeration of the lubricant to harness more stearate particles which slide or adhere on 
the excipient surface36. Therefore, the adhered particles, once delaminated, no longer spread 
over the excipient surface during mixing. This tendency of the particles to delaminate may 
make some forms of MgSt perform better as a lubricant than others under given mixing 
times31. 
 
The lubricant properties of pure MgSt are influenced by many factors such as the particle  
size, the surface area, the crystal structure of the compound and more specifically the  
crystal spacing which is dependent on the hydration state37. 
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According to Ertel and Carstensen38 the lubrication properties of pure MgSt depend on the  
moisture content and the crystal structure. Furthermore, studies suggest that the batch with  
smaller particle size and larger surface area has considerably better performance38. 
 
1.4.2 Effect of fine excipient particles on carrier based DPI formulations 
 
The amount of fine carrier particles, the shape of the particle size distributions and the 
surface roughness of the coarse carrier particles in a dry powder inhaler formulation play a 
key role in drug deposition. It has been reported in the literature that the addition of fine 
carrier particles in a powder mixture improves the drug deposition through optimizing the 
drug-carrier interaction. Fine carrier particles may form agglomerates with micronized drug 
and therefore effective respiratory delivery will require the dispersion of the drug from the 
agglomerate using energy generated from the inspiratory airflow of the patients39,40. 
 
1.4.2.1 The influence of lactose fines on a carrier based DPI formulation 
 
The inclusion of fines in carrier-based DPI systems is an extensively investigated and 
useful technique for the improvement of formulation performance. Carriers containing 
greater proportions of intrinsic fines give better performance41,42, and can be decreased by 
their removal.  
 
The addition of fine particles of lactose or one of many excipients to a formulation 
increases performance, although this may be at the cost of decreasing emission of drug 
from the device. The optimum median particle size for additional fines appears to be 
approximately 5-10μm43. 
 
1.4.2.2 Removal of intrinsic fine particles from a lactose carrier  
 
A number of studies conducted have incorporated pre-treatment of a coarse lactose carrier 
to remove any existing intrinsic fine particles, in order to allow a more accurate 
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quantification of the effects of adding fines to a formulation. In such cases, the removal of 
intrinsic fines resulted in a decrease in the performance of the formulations and the findings 
were in accordance with findings of studies suggesting that formulations containing the 
highest proportions of intrinsic fines have the greatest aerosol deposition performance41,42.  
study conducted by Islam et al (2004) 44 investigated the performance of salmeterol 
xinafoate containing different grades of carrier lactose modified by wet decantation. The 
results suggested that as the number of lactose particles <5μm in the carrier increased, the 
fine particle fraction (FPF) increased up to the maximum when the proportion of the 
intrinsic lactose fines was 15% where thereafter no improvement in performance was 
observed44.  
 
In this study, two types of carriers were used in preparing the formulations. The first type 
was Lactochem which was used as-supplied as a sieve fraction in the range 63-90μm and 
the second type was Nanolac which is etched lactose. The removal of fine lactose particles 
in Nanolac was performed by an etching process and the effect of the fines was investigated 
in formulations containing MgSt to examine any improvement in the performance. 
 
 
1.4.2.3 Addition of lactose fines in a formulation 
 
As the presence of fines in the carrier material is one of the most important factors  
influencing the formulation performance, extended research has been conducted. Zeng et al  
(1996) 45 investigated the effect of the addition of 6% fines to a carrier-based formulation  
containing 1.5% salbutamol sulphate and lactose, which resulted in an increase in the FPF  
by up to 116%.  
 
In addition, another study performed by Zeng et al (2001) 46 using a formulation containing 
again salbutamol sulphate, lactose ad lactose fines resulted in an increase in fine particle 
dose (FPD) by up to 51%. The majority of the studies performed, found that the addition of 
lactose fines to the formulations resulted in an increase in FPF or in FPD of the  
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drug. Furthermore, the concentration of the fines in the formulation has also an effect in the 
performance of the formulation. However, each study performed on the variation of the 
amount of lactose fines, suggested a different optimum concentration which could be due to 
the different methods and materials used. 
 
1.5 Current pharmaceutical aerosol testing devices 
 
An in vitro apparatus is used as a substitute for the respiratory tract, acting as a surrogate 
particle collector. They reproduce, to a reasonable degree, the aerosol deposition 
characteristics within the respiratory tract. These devices classify the particles collected 
according to their aerodynamic diameters, therefore indicating the extent to which the 
sample would have penetrated the respiratory tract.  Impactors are the instruments of choice 
for the in vitro assessment of delivery efficiency of inhalation products and the reason is 
because they allow the aerodynamic size distribution of the entire inhaled dose to be 
characterised in a way that is specific to the drug and which ignores the size of any 
excipient particles that are present47. Pharmacopoeia acceptable in vitro testing apparatus 
include the Andersen Cascade Impactor (ACI), the Marple Miller Impactor, the Multi Stage 
Liquid Impinger (MSLI), the Twin Stage Impinger (TSI) and the recently developed Next 
Generation Impactor (NGI).  
 
The MSLI and TSI which are used in this study will be described in more detail in Chapter 








1.6 Aims of the study 
 
As mentioned, different strategies have been employed in order to improve the aerosol 
deposition performance of carrier-based DPI formulations by affecting the interparticulate 
interactions between particles in them.  It is clear that the investigation of the 
interparticulate interactions between the variable formulations compared to their aerosol 
performance may be useful to find out the mechanism by which MgSt and fines improve 
the formulation performance. A better understanding of these mechanisms is important to 
determine the optimum concentration of MgSt and fines of lactose to achieve better aerosol 
performance and more efficient protection at different environmental conditions, as well as 
promote faster formulation development. 
 
The primary aim of this study is to investigate the influence of the addition of MgSt and the 
presence of lactose fines on the aerosol deposition performance of DPI formulations and 
consequently the drug-excipient adhesion properties. In addition, investigative work was 
also conducted to investigate and understand the prospective influence of the environmental 
conditions such as relative humidity and temperature on the stability of the DPI 
formulations and if the addition of MgSt would protect the formulations from de-stabilising 
under these conditions. By employing different concentrations of MgSt on carriers with 
different morphology, formulations with varying adhesive and cohesive interactions were 
produced, enabling the exploration of their relationship to in-vitro formulation 
performance. 
 
In addition, the potential use of an in-line optical sensing technology, the VariDose, is 
investigated (Chapter 5) which could rapidly test the performance and predict the 
variability in the delivery characteristics of both nasal and inhalation based formulations. 
The VariDose device, could lead to an effective and efficient system for testing aerosol 
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General materials and methods 
 
2.1 Materials  
 
All the materials and their source used during this study are listed in table 2.1. Materials 
were first characterised in terms of sample morphology and particle size. All organic 
solvents used in this study were of at least analytical grade. Ceramic balls of 10mm 
diameter were used for high shear ball milling. The lactose was vibrated through a nest of 
sieves to obtain a 60-90μm sieve fraction, which was used throughout the study. 
 
Materials Source 
   Micronized budesonide Sicor, BN:6157/M1, Santhia, Italy 
 
   α-lactose monohydrate (Lactochem®) Lactochem, Borculo, Holland 
63-90μm fraction obtained by sieving 
 
  10% etched α-lactose monohydrate 
  (Nanolac®) 
University of Bath, BN: DINA01 
 
   Sorbolac 400 (milled α-lactose  
                        monohydrate)  
Meggle GmbH, Wasserburg, Germany 
   Magnesium Stearate Fischer Chemicals, BN:9880836,  
Loughborough, UK 
 
   Acetonitrile Fischer Scientific Ltd, Loughborough, UK 
 
   Methanol Fischer Scientific Ltd, Loughborough, UK 
 
   Water Obtained by reverse osmosis 
MilliQ, Molsheim, France 
 
 
Table 2.1 Materials used throughout this study. 
 
It should be stated that for the remainder of this thesis α-lactose monohydrate and 10% 
etched α-lactose monohydrate will be referred to as Lactochem and Nanolac, respectively. 
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2.1.1 Drug material 
 
Budesonide is an inhaled glucocorticosteroid which is widely used in the treatment of 
asthma. It has potent anti-inflammatory actions and thus reduces the inflammation and 
hyper-reactivity (spasm) of the airways caused by asthma. The chemical structure of 
budesonide is shown in figure 2.1. 
 
Molecular formula: C25H34O6 
 
Figure 2.1 Chemical structure of budesonide. 
 
 
2.1.2 Carrier structure 
 
 
Lactose is a disaccharide, widely used as a carrier in inhalation formulations. Figure 2.2 
shows the chemical structure of α-lactose monohydrate. 
Molecular formula: C12H22O11 
 
 






2.2.1 Scanning electron microscopy (SEM) 
 
 
The morphology of the drug particle surfaces used throughout the investigation was 
investigated by SEM, which is a microscope that uses electrons rather than light to generate 
a high resolution image of a conducting sample. It achieves this by collecting and analysing 
secondary electrons emitted as a result of high energy electron beam collisions. Scanning 
electron microscopy is used to make a qualitative analysis of the particle shape and size of 
the various materials used. 
 
Samples were fixed to sticky carbon tabs mounted on aluminium stubs. They were then 
coated with gold using a splutter coater (model S150B, Edwards High Vacuum, Sussex,  
UK) and examined using a scanning electron microscope (model JSM6310 or JSM6480, 
Japanese Electron Optics Ltd, Tokyo, Japan) at 10 KeV. Inspection of the SEM images of 
the micronised drug (Figure 2.3) showed the budesonide particles to have both columnar 
and irregular plate-like crystal shape. Budesonide particles were present in the form of 






Figure 2.3 Representative SEMs of the micronised budesonide at A) x3000 and B) x8500 
magnification. 
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2.2.2 Particle size analysis 
 
The particle size distribution (PSD) of the materials was investigated using laser light 
scattering. Particle size characterisation is critical for inhalation preparations since they 
may influence the stability, flowability and aerolisation performance of the formulations. 
Laser light scattering involves measuring the intensity pattern of scattered light from a laser 
passing through a particulate sample1. 
 
Light scattering is a popular technique used for determining the particle size distribution of 
a material. The diffraction of the laser light results from the interaction of the light with the 
particles and can be described mathematically by Fraunhofer or Mie theory. The Mie theory 
is the rigorous solution for light scattered from a sphere2.For particles smaller than the 
wavelength of the incident light, the Mie theory is reduced to the Rayleigh theory. When 
particles are much larger than the wavelength of the incident light, the Mie theory 
simplifies to the Fraunhofer theory3. 
 
Gustav Mie in 1908 published a solution to the problem of light scattering by homogeneous 
spherical particles of any size. The Mie theory is a complete mathematical-physical theory 
of the scattering of electromagnetic radiation by spherical particles.It takes into account 
both the diffraction and diffusion of the light around the particle, in its medium. According 
to the Mie theory, the scattering angular pattern is symmetrical along the axis of incident 
light for perfect spheres1. However, to use this model it is necessary to know certain 
parameters like the complex refractive index (m) of both the sample and the medium3. 
 
The Fraunhofer theory is applied to large particles, typically >30μm3.When the particle is 
much larger than the wavelength of light or the materials are highly absorptive, the edge 
effect (diffraction) of particles contributes more to the total scattered light. In this theory, a 
particle is assumed to be producing a scattering pattern as it were an opaque circular disk of 
the same projected area placed normally to the axis of the incident beam. The Fraunhofer 
theory provides a much easier analytical solution for particle sizing as compared to the Mie 
theory.  
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For particles smaller than the wavelength the incident light, the scattered light is not 
concentrated in the forward direction but spreads to the side and rear. Modern light 
scattering instruments used for measuring particle size distribution rely mainly on the Mie 
theory to obtain analytical results. Thus, the basic assumption for the instruments is that 
particles are perfect spheres1. 
 
Particle size analysis was carried out in the dry state. Powders were dispersed with 
compressed air at 3 bar through a RODOS dry disperser fed by an ASPIROS micro-dosing 
unit before sizing with a HELOS laser diffraction sensor (all from Sympatec GmbH, 
Clausthal-Zellerfeld, Germany). The particle size analysis was performed using WINDOX 
4.0 software (Sympatec GmbH, Clausthal-Zellerfeld, Germany). 
 
The particle size distribution was calculated and represented as a volume distribution, and 
was also characterized by the 10th, 50th and 90th percentile of the cumulative particle 
undersize frequency distribution. All samples were prepared and analysed in triplicate. 
 
2.2.3 In vitro apparatus for determination of aerodynamic properties of inhalation 
formulations 
• Multi Stage Liquid Impinger (MSLI) 
 
The multi stage liquid impinger (MSLI) is a five-stage cascade impactor for determining 
the aerodynamic size distribution of DPIs and pMDIs. The MSLI has no interstage loss and 
is suitable for use throughout the range 30 to 100 L/min. It consists of four classifying 
stages and a filter. The collection stages are kept moist by the addition of mobile phase, 
which helps avoid the problem of re-entrainment of powder sometimes experienced when 
using more conventional impactors. It separates the particles into five fractions with cut off 
diameters ranging from 18 down to 3μm. The MSLI apparatus consists of a throat, four 
classifying stages into which 20ml of mobile phase is introduced such that the entire 
surfaces of all the glass plates are completely wetted and a fifth dismantled stage on top of 
which a filter paper is placed48.  The MSLI is described in more detail in section 3.4.5.  
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• Twin Stage Impinger (TSI) 
The TSI is the first device which was used to assess pulmonary drug delivery through 
inertial impaction. It has two stages and a representative throat. It first appeared in the  
British Pharmacopoeia and is used for the initial screening of inhalation devices and 
formulations. 30 ml of the mobile phase is introduced into the conical measure (stage 2) of 
the apparatus and 7 ml of the mobile phase into stage 1. These wet stages of the impinger 
make it less prone to errors resulting from particle re-entrainment and they also create a 
humid environment similar to that in the lungs49. However, the TSI has inherent limitations 
in the adequacy of size distribution, since it has an effective cut-off diameter of 6.4 μm49 but 
it still is a useful and convenient method of in vitro assessment of delivery efficiency of 
inhalation products. 
 
             
                                   
 
Figure 1.4 Schematic representation of a Twin stage impinger, adapted from the British  






2.2.4 Chemical determination of drug concentration 
 
2.2.4.1 Preparation of mobile phase 
 
 




2.2.4.2 Preparation of standard solutions of budesonide 
 
 
Stock solutions of budesonide of concentrations 0.1, 0.25, 0.5, 2, 10, 50 mcg /ml were 
prepared. The stock standard solution was prepared by accurately weighing out 0.0205g of 
budesonide into a 500ml volumetric flask, which was made up with 150ml of water and 
methanol. Each stock solution was sonicated for 20 minutes to ensure dissolution and 
allowed to cool at room temperature and made up to the mark with 30% water and 
methanol. Serial dilutions of the stock standard solution were carried out using calibrated 
(class A) volumetric laboratory pipettes, to produce the stock solutions with the 
concentrations stated above. 
 
 
2.2.4.3 Preparation of powder formulations 
 
 
Lactochem® was sieve fractioned using a sieve shaker (Endecotts sieve and sieve shaker, 
London,UK). A test sieve with an aperture width of 90μm was placed over a test sieve with 
an aperture width of 63μm. The 63-90μm sieve fractioned lactose was subsequent blended 
with micronised budesonide in a ratio of 67.5:1 w/w. The blending procedure involved 
initially adding a mass of lactose, approximately double the amount of budesonide to be 
incorporated in the powder blend into a stoppered sample glass vial. The total mass of 
budesonide was then directly weighed on top of the layer of lactose. The glass vial was then 
placed on a Whirlymixer (Fisons Scientific Equipment, Loughborough, UK) in a slanting 
position at 45° and mixed for 1 minute. The blend was further diluted by the addition of 
lactose. The amount of lactose was equivalent to the total amount of drug and lactose in the 
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glass vial and mixed again on the Whirlymixer. The geometric addition of the lactose and 
mixing was repeated until all of the lactose was incorporated into the blend.  
 
The glass vial was then placed in a Turbula mixer and mixed at 46 rev/min for 30 minutes.   




2.2.4.4 Capsule filling and storage 
 
 
Hydroxypropyl methylllulose (HPMC) capsules, size 3, (Qualicaps, BN: EO404632,  
Shiongi Qualicaps, Madrid, Spain) were filled with 25 ± 3 mg of the powder blends, such 
that each capsule contained a nominal dose of approximately 200 ± 20μg of budesonide.  
The filling was performed manually and filled capsules were stored in a sealed container at 
a controlled environment of 44% RH created by a saturated solution of potassium 
carbonate. 
 
2.2.4.5 Drug content uniformity  
 
Uniformity testing can be used as an indirect method of evaluating the interaction between 
the drug and the carrier particles. For example, if the uniformity is low, the drug has not 
been well dispersed. This may occur because the cohesive forces between the drug particles 
are high and more energy is required to break up agglomerates of drug particles. 
Alternatively, it may be that the cohesion between drug particles is much higher than the 
adhesion to the carrier particles leading to an unstable formulation. In this case, the drug 
distribution becomes less uniform over time as the drug particles will tend to re-








2.2.5 Drug content determination 
 
   2.2.5.1 High Performance Liquid Chromatography (HPLC) 
 
The HPLC system consisted of a JASCO AS950 intelligent sampler, a JASCO PU-980 
intelligent HPLC pump, a JASCO 975 UV/VIS detector and a Waters Spherisorb 15 cm, 
5μm ODSI column. The detection wavelength was λ=244 nm, the flow rate was 1.5 
ml/min, the pressure was less than 500 kg/m2, the injection volume was 100μl, the analysis 
time was 5 minutes, the retention time was 3.15 minutes and the mobile phase was that 
described above. Injections of all solutions analysed were made in duplicate. 
 
The standard solutions of budesonide prepared, were analysed using the HPLC method.  
Data were recorded and integrated using AZUR-0SIRIS Chromatography Software V3.0  
(Theix, France) The mean value of the area under the curve (AUC) of the two injections for 
each solution was calculated for the peak which represented budesonide and a calibration 
graph was constructed. An example of the calibration graph is shown in figure 2.5. 
 
  
                        
 





2.2.6 Statistical analysis 
 
 
Statistical analysis of data was carried out using Minitab for Windows. One-way  
ANOVA (analysis of variance) was used to determine the variance of data. Fisher’s pair-
wise analysis was carried out to determine the level of significance. Statistical significance 
was defined at either a limit of P<0.05 or P<0.01. 
 
The average and deviation of normal distribution populations were expressed as arithmetic 
mean ( x ) and standard deviation (SD). Arithmetic mean ( x ) was calculated by equation 
2.1: 
 











The standard deviation (SD) was calculated by equation 2.2: 
 
 














The relative standard deviation RSD (%) also known as the coefficient of variation was 
calculated by equation 2.3: 
 
   Equation 2.3                   x














As described, the materials used throughout the study underwent an extensive 
physicochemical characterisation. The physicochemical properties of the materials could 
possibly be modified during their processing, handling and storage and therefore their 
characterisation would further help gain a better understanding on the changes and the 
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The effect of the addition of Magnesium Stearate 





Magnesium stearate (MgSt) is widely used as a lubricant in the manufacture of 
pharmaceutical solid dosage forms1. Previous studies have shown that the addition of MgSt 
to pharmaceutical DPI formulations increased aerosol deposition performance by 
modifying the adhesive interaction between the drug and the carrier, thus facilitating the 
detachment of the drug particles from the coarse carrier during aerolisation2. It has been 
reported that MgSt can displace the fine active ingredient from coarse monodisperse 
carriers in mixtures based on its influence on the force balance of particle interactions. 
Magnesium stearate as suggested by these studies, should form weaker drug-lactose 
interactions within the blends. It is well established that drug dispersion within the dry 
powder formulation is the key factor in efficient pulmonary drug delivery. Without the 
introduction of a force lowering agent, such as lubricant, a larger amount of energy would 
be required to overcome the adhesive interaction for the dispersion of the drug from the 
lactose surface2.  
 
In a related study, the coating of MgSt to a lactose surface by mechanofusion modified the 
interfacial interactions between budesonide-lactose to such a degree that the drug 
completely segregated form the carrier leading to a high coefficient of variation in content 
uniformity and variable drug delivery performance2 
  
In solid dosage forms, magnesium stearate is used as a lubricant to aid the efficient ejection 
of tablets through reducing the frictional forces exhibited between the compressed tablet 
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and the die wall during operation. If there is sufficient shear forces generated during the 
mixing process  MgSt may form a thin film around host particles, which can interferes with 
the bonding and adhesive properties of the host particles by acting as a physical barrier.3 
 
Depending on the shear forces induced during powder mixing and processing time. MgSt 
may coat the host particles with varying thicknesses of the lubricant, from a molecular film 
up to a particulate film. The formation of a MgSt film will lead to a significant decrease in 
the adhesive tendency of the host particle due to the lowering of its surface free energy and 
the coefficient of friction. The use of force control agents, in particular MgSt, on the 
behaviour and performance of model DPI formulations has been investigated by Begat et 
al. (2005) 2. Their work highlighted the potential advantages and disadvantages for the 
introduction of MgSt in DPI formulations. However, they used a highly intensive co-
processing system “Mechanofusion” to ensure the liberation of the MgSt layers in forming 
a complete coating over the host particles. The high degree of shear was sufficient to 
modify the adhesive interactions between budesonide-lactose and salbutamol sulphate-
lactose to such an extent that there was no observable interaction between the drug and 
excipient. This led to the segregation of the drug from the excipient and the formation of a 
cohesively led drug-drug system, which is undesirable 2. 
 
The aim of this study was to investigate the influence of various concentration of MgSt on 
the properties and behaviour of carrier based DPI formulations but through a medium-high 
shear process, where the degree of lubrication and anti-adhesive properties of the excipient 
should not be sufficient to completely segregate the active pharmaceutical ingredient from 
the excipient surface. An inhaled corticosteroid, budesonide, was used as a model drug for 












α-Lactose monohydrate (Lactochem®) was supplied by Borculo Whey (Chester, UK). The 
as supplied lactose was vibrated through a nest of sieves to obtain 63-90 μm sieve fraction, 
which was used throughout the study. Micronised budesonide was supplied by Sicor (Batch 
no. 6157/M1, Santhia, Italy). A 10% etched lactose (Nanolac) was produced according to 
the procedure outlined by El-Sabawi et al. (2006). Magnesium stearate was supplied by 
Fisher chemicals (Batch no. 9880836, Loughborough, UK). The acetonitrile and methanol 
were of HPLC grade and were obtained from Fisher Scientific (Loughborough, UK). Water 
was purified by reverse osmosis (MilliQ, Millipore, Molsheim, France). Hydroxypropyl 
methylcellulose (HPMC) capsules (size 3) were supplied by Qualicaps (Batch no. 
EO404632, Shiongi Qualicaps, Madrid, Spain). Potassium carbonate anhydrous was 
supplied by Acros Organics (Batch no. A018189301, New Jersey, USA) and was used to 
maintain a constant relative humidity of 44% RH for the storage of the formulations in 
hermetically sealed containers. Ceramic balls of 10mm diameter were used to create high 
shear energy during blending. 
 
3.3 Methods 
3.3.1 Scanning electron microscopy 
 
The morphology of each blend, the lactose and budesonide were investigated using a 
scanning electron microscope, (JEOL 6310, Japanese Electron Optics Ltd, Tokyo, Japan) at  
10 KeV.  The samples were sprinkled onto adhesive black carbon tabs, which were pre-
mounted on aluminium stubs and coated with gold using a splutter coater (S150B, Edwards 








3.3.2 Particle size analysis 
 
The particle size distribution of the non processed samples were determined by laser light 
scattering, using a Sympatec laser light diffraction article size analyser (Sympatec,  
Clausthal-Zellerfeld,Germany). The instrument was equipped with a RODOS powder 
dispenser and depending on the powder particle size to be analysed an R3 lens or an R4 
lens was used. The R4 lens could be used to observe large particles (size range of 0.5 to 
350μm) that could not detected by an R3 lens. The inlet pressure on the equipment was set 
at 2 bars and a speed of 50mm/s. A RODOS dispenser (Sympatec) was used for a 
consistent fluidisation of the powder sample, which was fed with an ASPIROS micro-
dosing unit before sizing with a HELOS laser diffraction sensor.  
 
The particle size analysis was performed using WINDOX 4.0 software. (Sympatec,  
Clausthal-Zellerfeld,Germany). Size distributions and values presented are the average of 3 
determinations. The particle size distribution of the aerosol cloud, emitted from a 
Cyclohaler® by each of the ten processed formulations described was determined using a 
HELOS laser diffraction sensor and an INHALER module (both from Sympatec GmbH, 
Clausthal-Zellerfeld, Germany). The flow rate through the INHALER module was set at 
60L/min and the mouthpiece of the Cyclohaler® was fitted directly to the measuring 
chamber, to enable measurement of the particle size distribution of the aerosol cloud 
immediately after emission. For each measurement, a size 3 HPMC capsule filled with 25 ± 
1 mg of the test formulation was inserted into the Cyclohaler® opened by piercing it and its 
contents aerosolised through the laser of the diffraction sensor for 10 ms. Particle size 
analysis was performed using WINDOX 4.O software (Sympatec GmbH, Clausthal- 











3.3.3 Preparation of surface etched α-lactose monohydrate (Nanolac®) 
 
 
A saturated solution of lactose in water was prepared by the addition of 300g lactose to  
1000ml of water and continually stirred at a temperature of 25°C for 30 minutes. The 
temperature within the vessel was controlled to within 0.1°C via a refrigerated controlled 
water bath (Haake, DC5, Fisons Scientific Equipment, Loughborough, UK). After the 30 
minutes, 400 ml of the saturated solution was removed from the vessel, filtered under 
vacuum through a 0.2μm filter, and transferred to a dissolution cell, which was maintained 
at the saturation temperature. An accurately weighed mass of 63-90μm sieved α-lactose 
monohydrate (250mg) was added to the saturated solution in the dissolution cell and 
continually stirred as the temperature within the vessel was gradually raised to 35°C for 2 
hours. A well-controlled etching of the lactose particles was achieved by forming an 
undersaturated solution of the lactose with increasing temperature. The difference between 
the initial temperature (25°C) and the final (35°C) is referred to as the etching temperature, 
and with knowledge of the solubility of the lactose at various temperatures and the initial 
amount of mass added the percentage of this mass which had been etched can be pre-
determined and controlled . After the 2 hours, the solution in the dissolution cell was 
filtered through a 0.2μm filter and washed out thoroughly with ethanol, in which lactose is 
practically insoluble. The resulting lactose was collected in a Petri dish and left to air dry 
for a week and then sieved again through a nest of sieves for 1 hour to obtain 63-90μm 
sieve fraction4. The 10% etched lactose produced will be referenced as Nanolac throughout 
this study. In addition to the efficient dissolution of fine lactose particles from the surfaces 
of the coarser particles, the process further etches the surface asperities present on the 
excipient producing a highly smooth lactose surface, hence the name Nanolac. 
 
3.3.4 Preparation of carrier based DPI formulation blends 
 
 
Budesonide was blended with both forms of lactose (Lactochem® or Nanolac®) in the ratio 
of 1:67.5% w/w. The formulations were blended through geometric mixing. Firstly, the  
Nanolac® or Lactochem® was either processed with or without various concentrations of the  
 45
MgSt and then budesonide was added to the blend. The concentrations of MgSt in the pre-
blend were 0.125, 0.25, 0.5, and 1.0 %w/w.  The processing of the MgSt with the lactose 
involved initially adding a mass of lactose which was approximately double the amount of 
MgSt to be incorporated into a glass vial. The total amount of MgSt was then added onto 
the layer of lactose. Three ceramic ball bearings (10mm in diameter) were then added to the 
blend. The ball bearings were used to induce the shear forces required in the mixing process 
to liberate and to coat the lactose with the force control agent. The vial containing the 
excipients and the ball bearings where mixed for 1 minute on a Whirlimixer (Fisons 
Scientific Apparatus, Loughborough, UK) at a slanting position at 45°. The blend was 
further diluted by lactose. The amount of lactose was equivalent to the total amount of the  
MgSt and the lactose in the glass vial. The glass vial was then stoppered and mixed via the  
whirlimixer, using the settings described above. The geometric addition of the lactose and 
the mixing were repeated until all the lactose had been incorporated into the blend. The 
final formulation was then put in the Turbula mixer (Glen Creston, Stanmore, UK) for 40 
minutes at 46 revolutions per minute. 
 
Upon the preparation of the pre-blend, 3.968g of the processed lactose was accurately 
weighed into a separate container. The budesonide was then blended geometrically with the  
MgSt-lactose pre-blend, following the same procedure as above. Briefly, a small amount of 
the pre-blend and a fixed amount of budesonide (0.032g) was mixed for 1 minute using a  
Whirlimixer (Fisons Scientific Apparatus, Loughborough, UK). More of the processed 
lactose was added in geometric quantities, followed by mixing with the Whirlimixer for 1 
minute after each addition. This was done until all the blend weighed out was added to the 
test tube. The blend was then mixed in a turbula mixer (Turbula, Glen Creston Ltd,  
Stanmore,UK) at 46 revolutions per minute for thirty minutes. Geometrically produced 
blends of the unprocessed (Lactochem) lactose with budesonide were also produced using 
the procedure discussed above. 
 
The blend masses and concentrations for the various formulations prepared for both  
Lactochem and Nanolac preparations are tabulated in tables 3.1 and 3.2, together with their 
characteristic letter designated for each blend prepared.   
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Table 3.1 Blend masses and concentrations of lactose and MgSt for the prepared blends. 
 




Amount of MgSt 
(g) 
A Nanolac 0.125% 7.9901 0.0100 
B Lactochem 0.125% 7.9900 0.0100 
C Nanolac 0.25% 7.9800 0.0203 
D Lactochem 0.25% 7.9802 0.0202 
E Nanolac 0.5% 7.9607 0.0403 
F Lactochem 0.5% 7.9609 0.0404 
G Nanolac 1.0% 7.9200 0.0800 
H Lactochem 1.0% 7.9200 0.0800 
 
  Table 3.2 Blend masses of the pre-blend and drug for the study.  
 
Blend Amount of 
Nanolac/Lactochem-
MgSt blend (g) 
Amount of 
budesonide (g) 
A 3.9682 0.0320 
B 3.9685 0.0320 
C 3.9684 0.0325 
D 3.9686 0.0320 
E 3.9680 0.0322 
F 3.9689 0.0322 
G 3.9687 0.0324 
H 3.9683 0.0320 
I (control) Nanolac only-     3.9685 0.0325 




3.3.4.1 Drug content uniformity 
 
 
Drug content uniformity was performed to ensure that the budesonide was blended 
uniformly with the lactose upon powder mixing. Content uniformity measurements were 
undertaking by evenly spreading the formulation on a piece of paper and randomly 
sampling ten samples of approximately 25 ± 2 mg from the powder blend. The samples 
were accurately weighed into 100ml volumetric flasks and made up with the HPLC mobile 
phase. The samples were then sonicated for 20 minutes to ensure that the powder was 
completely dissolved before the testing for drug uniformity. 
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The concentration of budesonide was measured by high performance liquid 
chromatography (HPLC). Each solution was run in duplicate through the HPLC machine.  
The ratio of budesonide to lactose of each sample was determined and the drug uniformity 
of the mixture was measured by the percentage relative standard deviation (%RSD). A 
value less than 6.0% is generally regarded as acceptable.  
 
 
 3.3.4.2 Capsule filling and storage 
 
 
Hydroxypropyl methylllulose (HPMC) capsules, size 3, (Qualicaps, BN: EO404632,  
Shiongi Qualicaps, Madrid, Spain) were filled with 25 ± 3 mg of the powder blends. Thirty 
capsules were filled for each powder blend. The filled capsules were then stored under a 
controlled relative humidity of 44% and stored for at least 24 hours before testing, to allow 
the electrostatic charges induced during processing to decay.  
 
 
3.3.5 In vitro aerosolisation studies 
 
 
The pulmonary deposition of budesonide from each blend was assessed by the use of a  
Multi Stage Liquid Impinger (MSLI) (Copley Instruments Ltd, Nottingham, UK).  A 
general description of the MSLI and the conditions set for its operation are described in 
section 2.2.8.1 in Chapter 2. Ten capsules were fired from the Cyclohaler at 60 L/min with 
a 4 second exposure for each capsule. The capsule shells were removed from the cyclohaler 
and used in the analysis of device retention. The capsules and device were washed out with 
mobile phase into the same 100ml volumetric flask. The mouthpiece and throat were 
analysed together and stages 1 - 5 were washed out and analysed individually. All of these 
samples were analysed for their budesonide content using the HPLC method described 
above. The deposition of each formulation was measured in triplicates and a variety of  
parameters were utilized to characterise the deposition profiles of the budesonide.  
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3.3.5.1 Analysis of budesonide  
The concentrations of budesonide collected on the various stages of the MSLI apparatus 
were analysed using high performance liquid chromatography (HPLC). The HPLC system 
consisted of a 5μm Hypersil column (Hypersil MOS C8, Jones Chromatography Ltd, 
Hengoed, UK), a pump (Jasco PU-980, JASCO Corp., Tokyo, Japan) and a UV detector 
(Jasco UV-975). The mobile phase consisted of acetonitrile 35%, methanol 45% and MilliQ 
water 20%, running at a flow rate of 1.5 ml/min. The detector was set at a wavelength of 
244nm. The data were recorded and integrated using AZUR-OSIRIS Chromatography 
Software V3.0 (Theix, France). 
3.3.6 Statistical analysis 
Statistical analysis of the data was carried out using Minitab for Windows. One-way 
ANOVA (analysis of variance) was used to determine the variance of data. Fisher’s pair-
wise analysis was carried out to determine if the differences were significant. Statistical 
significance was defined within 95% (P<0.05) and 99% (P<0.01) confidence limits. The 
levels of significance obtained are indicated in the key on individual graph. 
 
3.4 Results and Discussion 
 
3.4.1 Scanning electron microscopy (SEM) 
  
 
Representative SEM micrographs of Lactochem and Nanolac particles are shown in Figures  
3.3 and 3.4, respectively. The figures suggest distinct variations in the amount of intrinsic 
fines adhering to the surface of the as-received Lactochem with respect to the surface 
etched lactose (Nanolac). Furthermore, the SEM images indicate a significant increase in 
the degree of surface smoothness of Nanolac (figure3.4) in comparison to Lactochem, 
whose morphology is characterised by a series of ridges and clefts (figure 3.3). These 
differences are also apparent upon processing with MgSt, where the formulations 
containing Nanolac having smooth edges (figure 3.8) and formulations containing 
Lactochem having rough edges and clefts (figure 3.7). This suggests that a smooth 
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continuous coating of the MgSt over the surface of the lactose particles may be more likely 
to occur for the Nanolac formulations. 
 
Clear differences in the degree of fine particulates were observed between blends from the 
lowest to the highest dose level. Lactochem formulations demonstrated a relatively higher 
presence of fine particulates on the larger lactose particles when compared to the equivalent 
dose level of Nanolac formulation, as well as a rougher surface topography of the lactose 
particle. As anticipated, the scanning electron micrographs of the formulation blends 
highlighted a high degree of agglomeration of the drug and increased segregation of the 
drug from the lactose surfaces with increasing concentrations of MgSt. This can be clearly 
observed for the highest concentration of MgSt (1%w/w), where loose and segregated 
agglomerates can be observed. This may suggest that such a high concentration of MgSt 
may reduce the force of adhesion between the drug particles and carrier excipient to such 
an extent that the drug segregation and agglomeration is favoured, as suggested by Begat et 
al. 2  
 
    
B) A) 
Figure 3.1 Representative scanning electron micrographs of Lactochem at A) x650 and  
B) x1600 magnifications. 
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A) B) 




A) B ) 
Figure 3.3 Representative scanning electron micrographs showing the control 






Figure 3.4 Representative scanning electron micrographs showing the control 





   
 




                 
 
    
 
Figure 3.5 Representative scanning electron micrographs of Lactochem and budesonide 
pre-conditioned with A) 0.125%, B) 0.25%, C) 0.5% and D) 1.0% w/w MgSt at x650 and  
x2200 magnifications. 
    
 








                  
                 
 3.6 Representative scanning electron micrographs of Nanolac and budesonide    
  
.4.2 Particle size analysis 
he particle size distribution of budesonide in table 3.3 followed a log-normal distribution, 
able 3.3 Particle size distribution statistics summary for budesonide. 
  Material d10 
(μm ± SD) 
d50 
(μm ± SD) 
d90 
(μm ± SD) 







 pre conditioned with A) 0.125%, B) 0.25%, C) 0.5% and D) 1.0% w/w MgSt at x650 and  






which is common for pharmaceutical materials. The table of data suggests that the 




   
(μm ± SD) 
 
Micronised 0.88 ± ± ±  0.77 
budesonide 






A graphical representation of the particle size and cumulative undersize distributions of the 







The sieved Lactochem sample and all MgSt processed Lactochem was found to have a 
considerably higher level of fine particles, compared to the Nanolac blends.  
These data suggest, however, that the surface etching process did not significantly modi
the coarse particle size but significantly reduced the percentage of intrinsic fines. The 
cumulative particle size distributions of the Lactochem and Nanolac samples are shown in 
figures 3.7 and 3.8, respectively and particle size distribution analysis summarised in ta
3.4. Although the d50 and d90 values of the carrier before and after etching were similar, the
d10 value was approximately double after the etching process, indicating that the etching 
procedure preferably dissolved the fine lactose particles present. This is further 
demonstrated by the proportion of particles in the carrier <10μm and < 5μm diameter, 
which were reduced by ~50% by etching. Thus, any apparent change in function
be a consequence of this removal of fines which is known to significantly influence the









Figure 3.8 bution of Nanolac®.  
able 3.4 Particle size distribution statistics summary of the carriers. 
(μm ± SD) (μm ± SD) (μm ± SD) 
μm 
(μm ± SD) 
% < 5 μm 
(μm ± SD) 





Materials d10 d50 d90 % < 10
Lactochem® 
 
14.72 ± 0.01 74.92 ± 0.17 129.70 ± 1.19 7.08 ± 0.07 3.84 ± 0.17 
Nanolac® 
 
24.48 ± 0.22 76.59 ± 0.89 126.74 ± 4.43 3.50 ± 0.03 1.84 ± 0.04 
 
 
e analysis of MgSt-lactose pre-blends 
e particles less than 10 and 5um for the 
 processed MgSt-Lactochem and MgSt-Nanolac pre-blends, shown in Figures 3.11 to 3.14
are summarised in Tables 3.5 and 3.6, respectively.  
 




            Blend Materials 
 
d10 
(μm ± SD) 
d50 
(μm ± SD) 
d90 
(μm ± SD) 
% < 10 μm 
(μm ± SD) 
% < 5 μm 
(μm ± SD) 
A 0.125% MgSt+Nanolac  
 
25.83±0.38 77.19±0.31 127.79±0.92 3.41±0.03 1.83±0.02 
C 0.25% MgSt + Nanolac 
  
56.46±1.39 92.39±0.92 140.95±1.19 2.02±0.23 1.27±0.12 
E 0.5% MgSt + Nanolac  
 
54.64±1.54 92.23±0.43 140.67±0.79 3.16±0.52 1.99±0.30 
G 1.0% MgSt + Nanolac  
 







(μm ± SD) 
d50 
(μm ± SD) 
d90 
(μm ± SD) 
% < 10 μm 
(μm ± SD) 
% < 5 μm 
(μm ± SD) 
B 0.125% MgSt+Lactochem 
 
16.24±0.92 75.69±0.06 129.42±3.08 6.59±0.3 6 3.68±0.16 
D 
 
0.25% MgSt + Lactochem 
 
10.48±0.60 68.41±0.60 130.35±3.20 9.60±0.53 5.19±0.25 
F 0.5% MgSt + Lactochem 
 
18.63±0.51 76.84±0.64 132.44±1.11 5.43±0.11 2.55±0.05 
H 1.0% MgSt + Lactochem 
 
14.61±0.58 74.89±0.98 129.03±1.42 7.10±0.21 3.58±0.09 







Table 3.6 Particle size distribution statistics summary of the MgSt- Nanolac pre blends. 
 
 
Due to the removal of the fines, the d10 and d50 for the Nanolac formulations are larger. 
Furthermore, there are significant differences in the amount of fine particle present in all 
Mgst-Nanolac blends with respect to the lactochem formulations.  
  
 
Figure 3.9 Cumulative particle size distributions of A) blend containing Nanolac and 





Figure 3.10 Cumulative particle size distributions of A) blend containing Nanolac and 
0.25% MgSt and B) blend containing Lactochem and 0.25% MgSt.
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Figure 3.11 Cumulative particle size distributions of A) blend containing Nanolac and 





Figure 3.12 Cumulative particle size distributions of A) blend containing Nanolac and 
1.0% MgSt and B) blend containing Lactochem and 1.0% MgSt
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3.4.2.4 Processed formulations 
 
Figure 3.13 show the particle size distributions of the aerosol clouds characterised by the 
Helios system at 60L/min for the Nanolac and Lactochem formulations following actuation 
from the single shot Cyclohaler DPI device. These data suggest that the Lactochem 
formulations exhibited a significant distribution of sub-20um fine particulates within the 
formulation and the presence agglomerates with a size range between 20 and 40µm, 
relative to the Nanolac formulations, which only indicated a small inflection between the 2 
and 3 microns followed by the presence of the coarse PSD.  
 
With the addition of increasing concentrations of MgSt to the Lactochem formulations 
there are differences in the particle size distributions of the aerosol clouds with respect to 
the Lactochem formulation. As show in Figure 3.14, while there are no observable 
differences in the particle size profiles with the addition of very low concentrations of MgSt 
(0.125%), there is a marked influence upon the addition of 0.25% MgSt (Figure 3.14(B)). 
The profile suggests that there is relative increase in the detection of particles in the 
respirable size range together with an increase in the amount of agglomerates in the 20-40 
µm size range. While there are similar effects for the addition of increasing concentrations 
MgSt their influence appear to be not as significant as the addition of 0.25% MgSt with 
Lactochem. These observations are supported by particle size distribution statistics shown 
in Table 3.17 for the Lactochem formulations, where the percentage of particles below 5µm 
was highest for the addition of 0.25%w/w MgSt.   
 
The addition of MgSt to the Nanolac formulations had a marked influence on the particle 
size distribution for all concentrations. Upon the addition of 0.125% MgSt there was an 
observable increase in the size distribution data both in the respirable size range and in the 
20-40 µm size range (Figure 3.15(A)). However, with increasing addition of MgSt the 
influence on the particle size distribution was observed only in the respirable particle size 
range (Figures 3.15 (B-D)). The particle size distribution statistics for the addition of MgSt 





 Figure 3.13 Representative particle size distribut y  ions of the aerosol clouds generated b











Figure 3.14 Representative particle size distributions of the aerosol clouds generated by the formulations of Lactochem and 







stributions of the aerosol clouds generate Figure 3.15 Representative particle size di d by the formulations of Nanolac and  
 budesonide pre-conditioned with A ) 0.125%, B) 0.25% C) 0.5% and D) 1.0% w/w MgSt at 25°C, 44%RH. 
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At 25°C, 44%RH 
d10 
(μm ± SD) 
d50 
(μm ± SD) 
d90 
(μm ± SD) 
% < 10 μm 
(μm ± SD) 
% < 5 μm 
(μm ± SD) 
J Lactochem+budesonide 
 
13.51±2.63 71.41±13.64 120.87±6.78 6.98±1.21 2.00±0.29 
B 0.125%MgSt+Lactochem 
+ budesonide 
7.29±1.04 71.85±11.59 119.65±9.12 13.69±2.29 7.18±1.10 
D 0.25%MgSt+Lactochem 
+ budesonide 
4.36±0.70 80.11±3.65 110.58±2.17 19.82±3.26 11.68±1.87 
F 0.5% MgSt +Lactochem 
+ budesonide 
5.02±1.54 47.29±12.08 97.80±7.09 20.49±3.16 10.52±1.71 
H 1.0% MgSt +Lactochem 
+ budesonide 





















At 25°C, 44%RH 
d10 
(μm ± SD) 
d50 
(μm ± SD) 
d90 
(μm ± SD) 
% < 10 μm 
(μm ± SD) 
% < 5 μm 
(μm ± SD) 
I Nanolac+budesonide  
 
52.78±1.88 90.26±2.48 135.13±2.60 4.68±0.90 3.61±0.69 
A 0.125% MgSt + Nanolac 
+ budesonide 
14.90±1.99 67.24±8.50 116.28±7.68 7.31±0.77 4.18±0.46 
C 0.25% MgSt + Nanolac 
 + budesonide 
34.62±2.89 85.35±2.24 130.66±2.95 8.30±0.88 6.56±0.72 
E 0.5% MgSt + Nanolac  
+ budesonide 
36.95±2.63 87.23±1.47 131.07±3.30 8.18±1.02 5.94±0.77 
G 1.0% MgSt + Nanolac  
+ budesonide 
23.38±4.61 88.69±1.68 139.36±2.26 11.52±1.10 8.57±1.23 
3.4.3 Drug content uniformity 
 
The drug content uniformity of all the Lactochem and Nanolac formulations are summarised in 
table 3.9 and 3.10, respectively. While all formulations have an acceptable %RSD the content 
uniformity for the non-MgSt processed lactose has a significant lower coefficient of variation. No 
























Table 3.9 Content uniformity of the five Lactochem formulations of budesonide,  
 





As shown in tables 3.9 and 3.10 the content uniformity analysis of the formulations indicated that 
all the formulations were well blended, showing a uniform distribution of the drug throughout the 
matrix, since their %RSD was <6%, which is the value commonly taken as sufficiently uniform 





Formulation %RSD SD 
















Table 3.10 The content uniformity of the five Nanolac formulations of budesonide  
 





As can also been seen from the tables, the % RSD values of the control formulations which did 
not contain any MgSt are significantly less than the %RSD values of the other formulations.  
However, there is no significant difference in the %RSD values between the formulations 
containing MgSt.  
 
 
3.4.4 In vitro aerosolisation studies 
 
Stage-by-stage deposition data for the Lactochem formulations containing increasing 
concentrations of MgSt are shown in Figure 3.16 and summarised in Table 3.11. These data show 










































   














































Figure 3.16 The deposition of budesonide, as a percentage of total recovered dose, for 
Lactochem and MgSt-Lactochem formulations at 25°C, 44%RH. (Mean ± S.D, n=3). 
*P<0.05, ** P<0.01: significant difference compared to Lactochem control formulation by 
ANOVA one-way. C & D: capsules & device).  
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Table 3.11 The deposition of budesonide as mean drug weight per shot (ug) at 25°C, 44% RH in the different stages of the  
MSLI for the Lactochem formulations and standard deviations (Mean ± SD), n=3. 
 
 
       Blend 
                  (Mean ± SD) 
                        (μg) 













            J Lactochem+ budesonide 
 
53.9±8.9 15.8±0.2 36.7±.4.8 16.8±3.3 15.2±5.1 16.6±6.0 6.3±3.2 
B 0.125% w/w MgSt + 
Lactochem+budesonide 
 
34.3±4.0 12.7±1.9 52.1±2.2 15.3±2.3 12.3±1.9 14.2±2.3 3.9±0.6 
D 0.25% w/w MgSt + 
Lactochem+budesonide 
 
70.3±14.6 11.1±2.2 43.5±7.1 14.7±1.8 25.8±6.4 46.1±12.7 20.0±8.0 
F 0.5% w/w MgSt + 
Lactochem+budesonide 
 
44.0±8.6 8.8±2.1 63.3±14.5 15.4±6.2 12.3±4.2 24.0±7.7 11.8±1.8 
H 1% w/w MgSt + 
Lactochem+budesonide 
 
33.0±2.2 17.0±9.8 77.9±10.9 24.4±6.5 9.8±2.4 10.7±2.3 3.1±0.2 
As shown in figure 3.16 the largest percentage of drug, as a function of the total recovered   
dose, remains in the capsule/device and the throat and upper stage of the MSLI . This  
suggested incomplete device emptying and inadequate removal of the active ingredient 
from the excipient surface upon aerolisation. The throat stage has been combined with the 
stage 1 of the MSLI due to the fact that there was no apparent difference in the amount of 
drug deposited in the throat between formulations and the fact that due to the configuration 
of the system (i.e. no preseparator) the majority of the excipient particles would fall into 
stage S1 of the impinger via gravity.   
 
The coating of the lactose with MgSt reduced the device retention of the active ingredient 
in all the formulations, although the addition of 0.25%w/w MgSt was not significant. This 
suggested greater removal efficiency of the formulation upon actuation which may relate to 
a possible modification in the flow and fluidisation behaviour of the formulation upon the 
introduction of the MgSt6. 
 
For the emitted fraction, significant differences in the deaggregation and deposition in the 
upper stages of the in vitro apparatus was determined.  For the throat and the first stage (S1) 
of the MSLI, the highest percentage of drug deposited was for the 1.0% w/w MgSt-
Lactochem (Blend H) formulation. This suggested that an excess of MgSt may have been 
processed with the lactose in reducing the drug-lactose interaction. As a result, the possible 
segregation of the active from the lactose surface and the creation of loose agglomerates 
may lead to an increase in the deposition of the active in the throat and S1 of the MSLI. The 
significant inter-variation in the throat and S1 deposition of the drug with varying 
concentrations of MgSt highlights the significant influence of the force control agent on 
modifying the fine balance of the inter-particulate forces within the formulation and how it 
may transform a system which was initially dominated by the adhesive drug-lactose forces 
into a cohesive drug-drug led system. The addition of 1.0% w/w MgSt has lowered the 
interactions between the drug and excipient to such an extent that it could possibly lead to 
an unstable formulation, subjected to undesirable segregation. The amount of drug 
deposited by the 0.125% and 1.0% w/w MgSt formulations were significantly higher 
(ANOVA p<0.01) compared to the amount of drug deposited by the control formulation 
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while the 0.25% w/w MgSt formulation was significantly lower (ANOVA p<0.01). From 
these data, an optimum performance in terms of reducing upper airway deposition was 
obtained for the addition and processing of 0.25% w/w MgSt with the Lactochem carrier.  
 
In stage 2 of the MSLI, the amount of drug deposited by the 0.25% w/w MgSt (Blend X) 
formulation was significantly lower (ANOVA p<0.05) than all the other formulations while 
the 1.0% w/w MgSt formulation was significantly higher (ANOVA p<0.05) than all other 
formulations. The other MgSt concentrations were not significantly different to the control 
formulation. The 1.0% w/w MgSt formulation was significantly lower (ANOVA p<0.05) 
than the control formulation in stage 3 of the MSLI, while the drug deposition for all other 
concentrations of MgSt were not significantly different. In the critical stage of the MSLI, 
stage 4, only the amount of drug deposited by the 0.25% w/w MgSt formulation was 
significantly higher (ANOVA p<0.01) than the control formulation. These data show that 
the amount of drug delivered in the aerodynamic size range 1.7-2.4 um for the 0.25%w/w 
MgSt processed lactose was approximately twice that for the control.  All the other MgSt 
processed formulations were not significantly different to the control formulation. 
 
The stage-by-stage deposition of budesonide for the Nanolac carrier with increasing 
concentrations of MgSt are shown in Figure 3.17 and summarised in Table 3.12. The 
deposition profiles of budesonide from Nanolac formulations are different to the 
Lactochem formulations. In contrast to Figure 3.16, the drug retention within the device 
and capsule for the Nanolac control formulation was very low (< 60%). This may be either 
may be a consequence of a change to the fluidisation behaviour of the carrier due to the 
etching process or more likely a change to the drug-excipient interaction due to the 
increased surface smoothness of the excipient particles. However, while there is efficient 
emission of the formulation via the Cyclohaler device, the increased amount of drug 
emitted is retained in the throat and stage 1 of the in vitro apparatus suggesting that the 












Figure 3.17 Deposition of budesonide, as a percentage of recovered dose for Nanolac 
formulations at 25°C, 44%RH. (Mean ± S.D, n=3) with increasing concentration of 
MgSt ( *P<0.05, 








































































** P<0.01: significant difference compared to Nanolac control 
formulation by ANOVA one-way. C & D: capsules & device)
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Table 3.12 The deposition of budesonide as mean drug weight per shot (ug) at 25°C, 44% RH in the different stages of the  
    MSLI for the Nanolac formulations and standard deviations (Mean ± SD), n=3. 
 
 
          Blend          (Mean ±SD) 
               (μg) 













I Nanolac + budesonide 
 
9.1±2.1 8.8±5.4 62.5±3.2 7.3±1.6 6.0±2.9 5.8±1.7 3.2±0.5 
A 0.125% w/w MgSt + 
Nanolac+budesonide 
 
31.2±3.7 8.5±0.1 51.9±10.0 9.1±0.7 9.4±1.6 11.0±1.5 4.6±01 
C 0.25% w/w MgSt + 
Nanolac+budesonide 
 
72.7±3.2 7.0±2.6 38.6±8.7 6.9±0.9 18.4±3.8 28.3±1.4 12.8±4.5 
E 0.5% w/w MgSt + 
Nanolac+budesonide 
 
62.8±7.0 7.5±1.8 38.8±9.1 8.5±0.9 20.8±4.2 24.5±5.0 14.6±3.0 
G 1% w/w MgSt + 
Nanolac+budesonide 
 









As would be expected, the introduction of MgSt may lead to a decrease in this interaction 
as suggested by an increasing device retention and a lowering in the percentage of the drug 
retained in the throat and stage 1. For the MgSt-Nanolac formulations, the optimum 
concentration for minimising upper airway losses is between 0.25%w/w and 0.5% w/w.   
 
The addition of MgSt led to a significantly increase in device retention, whereas in the 
throat and s1 the amount of drug was significantly lower. In stage 2 of the MSLI, the 
amount of drug deposited for the addition of 0.25% and 0.5% w/w MgSt formulations were 
significantly lower (ANOVA p<0.01) than the control formulation. The amount of drug 
deposited for other concentrations of MgSt were not significantly different. The amount of 
drug deposited on stage 3 of the MSLI for the addition of 0.25% and 0.5% w/w MgSt 
formulations were significantly higher (ANOVA p<0.05) compared to the control 
formulation. Once again, the amount of drug deposited by the other formulations was not 
significantly different. In stage 4 of the MSLI, the amount of drug deposited by the 0.25%, 
0.5% and 1.0% w/w MgSt formulations were significantly higher (ANOVA p<0.01) 
compared to the control formulation. In the filter stage, the amount of drug deposited for 
the 0.25% w/w (P<0.05), 0.5% and the 1.0% w/w (P<0.01) MgSt formulation were 
significantly higher than the control, suggesting that more drug reaches the lower airways 
of the respiratory tract and that the addition of MgSt to the formulations significantly 
improved aerosol deposition performance. 
 
These data suggest that the 0.5% w/w MgSt formulation exhibited the optimum 
aerosolisation performance, since it has the largest amount of drug deposit in stages 3 and 4 
which is associated with the deposition profile in the conducting airways of the respiratory 
tract. It should be noted that processing the Nanolac-MgSt materials with ball bearing will 
lead to an increase in the surface roughness of the lactose particles. Thus, this roughening 
process may also contribute towards the lowering of the adhesive interaction leading to the 
significant changes in the formulation performance with respect to the Nanolac 
formulations.  
Table 3.13 The deposition of budesonide in the MSLI from the Lactochem formulations at 25°C, 44%RH via a Cyclohaler 




                  (Mean ± SD) 
                     











J Lactochem+ budesonide 
 
161.1±4.3 107.3±13.2 38.0±13.3 23.5±7.8 35.0±9.5 
B 0.125% w/w MgSt + 
Lactochem+budesonide 
 
144.9±3.0 110.6±6.3 30.5±4.0 27.5±2.6 21.0±2.6 





92.0±.25.9 39.4±2.7 56.6±3.7 
F 0.5% w/w MgSt + 
Lactochem+budesonide 
179.6±24.7 135.7±32.8 48.1±13.1 26.5±3.6 35.4±3.5 
H 1% w/w MgSt + 
Lactochem+budesonide 
 
175.8±13.6 142.8±13.3 23.5±3.3 13.5±2.3 16.6±3.2 
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Table 3.14 The deposition of budesonide in the MSLI from the Nanolac formulations at 25°C, 44%RH via a Cyclohaler 




                  (Mean ± SD) 
                     











I Nanolac + budesonide 
 
102.7±4.9 93.6±3.0 15.0±1.8 14.5±1.2 16.0±1.4 
A 0.125% w/w MgSt + Nanolac 
+budesonide 
 
125.7±4.6 94.5±7.2 24.9±3.2 26.6±5.1 19.9±2.9 
C 0.25% w/w MgSt + Nanolac 
+budesonide 
 
184.6±17.4 112.0±15.4 59.5±6.7 32.2±2.1 53.3±3.3 
E 0.5% w/w MgSt + Nanolac 
+budesonide 
 
177.4±6.3 114.6±11.8 59.9±7.2 33.8±4.2 52.4±5.4 
G 1% w/w MgSt + Nanolac 
+budesonide 
 
80.5±9.0 56.6±5.6 22.5±1.7 28.1±2.7 40.0±2.8 
 










































Figure 3.18 A graph showing the relationship between the recovered dose and the  
concentration of Magnesium stearate of both types of formulations. (Mean ± SD,n=3) 
( *P<0.05, ** P<0.01: significant difference compared to the control formulations by  
ANOVA one-way. C & D: capsules & device) 
 
 
The in vitro deposition data for the addition of increasing concentration of MgSt for the 
Lactochem and Nanolac formulations are summarised in Tables 3.13 and 3.14, 
respectively, in terms of the recovered, emitted and fine particle dose together with the fine 
particle fraction as a function of the recovered and emitted doses. These data are shown 
graphically in Figures 3(.18, .19, .20 and.21). 
 
Figure 3.18 shows that that the recovered doses of the Nanolac formulations containing  
MgSt were statistically significant compared to the control formulation which did not 
contain MgSt. All of them were significantly higher, except the formulation containing  
1.0% w/w MgSt which was significantly lower than the control (ANOVA p<0.05). The  
0.125% w/w MgSt formulation was significantly higher (ANOVA p<0.05), as well as the 
0.25% and 0.5% w/w MgSt (ANOVA<0.01). The 0.25% w/w MgSt formulations have the 
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highest recovered doses, both with Nanolac and Lactochem and an increasing trend can be 
seen from the control until the 0.25% w/w concentration of MgSt, gets to its maximum at 
0.25% w/w concentration of MgSt and then starts decreasing. Therefore, it could be 
suggested that at the optimum concentration of 0.25% w/w MgSt, more drug is leaving the 
capsule and device and entering the respiratory tract. Consequently the 1.0%w/w 
MgSt+Nanolac+budesonide formulation has the lowest recovered dose. In the Lactochem 
formulations, all recovered doses of the formulations containing MgSt were higher than the 
control one, except the formulation containing 0.125% w/w MgSt which was lower.  
However, only the 0.25% w/w MgSt formulation was significantly higher compared to the  
Lactochem control formulation (ANOVA p<0.05). When comparing the Nanolac with the 
Lactochem formulations, Lactochem formulations have higher recovered doses, possibly 
suggesting that fines do play a significant role in this particular experiment. Lactochem 
having a rough surface with clefts and cavities makes the force of adhesion between the 
drug particles and its surface quite low since their contact area is small and very limited.  
Therefore only a small amount of energy is required to detach the drug particles from the 
carrier surface. On the other hand, Nanolac has a smooth surface, and therefore a large 
contact surface area between the drug particles and the carrier surface and therefore a high 
force of adhesion. Consequently, a large amount of energy needs to be applied in order to 







































Figure 3.19 A graph showing the relationship between the emitted dose and the  
concentration of Magnesium stearate of both types of formulations. (Mean ± SD,n=3). 
( *P<0.05, ** P<0.01: significant difference compared to the control formulations by  
ANOVA one-way. C & D: capsules & device) 
 
As shown in figure 3.19, only the emitted dose of the 0.25% w/w MgSt formulation 
amongst the Lactochem formulations was statistically significant (ANOVA p<0.05). The 
emitted doses of the other formulations were not significantly different, suggesting that the 
addition of MgSt to the Lactochem formulations did not have a dramatic change in the 
emitted doses, as well as the recovered doses which was discussed above. Only the addition 
of 0.25% w/w MgSt to the Lactochem formulation resulted in a significantly higher emitted 
dose, suggesting that the optimum concentration of MgSt required for the maximum 
amount of drug to enter the respiratory tract is 0.25% w/w. 
 
Amongst the Nanolac formulations, the emitted dose of the 0.5% w/w MgSt formulation 
was significantly higher (ANOVA p<0.05) compared to the control formulation and the  
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1.0% w/w MgSt formulations was significantly lower (ANOVA p<0.01). This low amount 
of drug of the 1.0% w/w MgSt formulation emitted to the respiratory tract could be due to 
the agglomerates (either MgSt agglomerates and/or drug agglomerates) being formed 
because of the increased concentration of MgSt which lowers the force of adhesion 
between the drug particles and the carrier surface therefore falling off the surface and 
existing as loose agglomerates which are too big and remain in the capsules and the device. 
The 0.5% w/w MgSt formulation has the largest amount of drug emitted compared to the 
other Nanolac formulations, therefore more drug is entering the RT. The other Nanolac 
formulations did not show a significant difference compared to the control formulation, but 
their recovered doses were significantly different, leading to the assumption that a large 
amount of the drug in those formulations gets deposited in the capsules and the device 
rather than entering the respiratory tract. 
 
Once again, the Lactochem formulations have larger emitted doses compared to their 
equivalent concentrations of Nanolac formulations. As discussed above, this is due to their 
difference in surface morphology influencing the interparticulate interactions between drug 
particles and the surface of the carrier. 
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Figure 3.20 A graph showing the relationship between the fine particle dose and the 
concentration of Magnesium stearate of both types of formulations. (Mean ± SD,n=3). 
( *P<0.05, ** P<0.01: significant difference compared to the control formulations by  
ANOVA one-way. C & D: capsules & device) 
 
The fine particle dose (FPD) represents the amount of drug that reaches the lower airways 
of the RT and is the concentration of drug deposited in stages 3-5 of the MSLI apparatus. 
Amongst the Lactochem formulations, only the FPD of the 0.25% w/w MgSt formulation 
was significantly different (ANOVA p<0.01) to the control formulation. The FPD of the 
other Lactochem formulations were not significantly different compared to the control 
formulation. The addition of 0.25% w/w MgSt to the formulation dramatically increased 
the FPD value to 3x times the value of the control formulation. The FPD of the 0.5% w/w 
MgSt formulation was increased but not significantly. The other formulations had a lower  
FPD compared to the control formulation but the difference was not significant. There is an 
increasing trend up to 0.25% w/w concentration of MgSt, where it has the greatest FPD and 
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then it starts decreasing gradually reaching the lowest FPD at the 1.0% w/w MgSt 
formulation. 
 
Amongst the Nanolac formulations, the fine particle doses of the 0.25% and 0.5% w/w  
MgSt formulations were significantly higher (ANOVA p<0.01), having values 
approximately 4x the value of the control formulation. The 0.5% w/w MgSt formulation 
has the highest FPD but only with a slight difference of 0.5μg to the 0.25% w/w MgSt 
formulation. The other formulations had higher FPD values than the control formulation 
but were not significantly higher. These data suggests that the addition of MgSt to the 
Nanolac formulations increases the FPD and especially the addition of 0.5% w/w MgSt has 
the greatest FPD. In addition, an increasing trend is observed starting from the control 
formulation up to the optimum 0.5% w/w MgSt concentration and then a sharp decrease to 
the 1/3 of the FPD value at the 1.0% w/w MgSt formulation.  



















































Figure 3.21 A graph showing the relationship between the fine particle fraction as a  
percentage of recovered dose and the concentration of Magnesium stearate of both types  
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of formulations. (Mean ± SD, n=3).( *P<0.05, ** P<0.01: significant difference compared 
to the control formulations by ANOVA one-way. C & D: capsules & device) 
 
As shown in figure 3.21 there is an increasing trend in the Lactochem formulations, 
reaching the optimum concentration of 0.25% w/w MgSt and then a decreasing trend is 
observed. The highest FPFRD in the Lactochem formulations is observed with the addition 
of 0.25% w/w MgSt, having a significant effect on the aerosol performance (ANOVA  
p<0.01). It could be suggested that for a formulation containing Lactochem and 
budesonide, the optimum concentration of MgSt that is needed to achieve the most efficient 
drug delivery is 0.25% w/w. A decrease in the performance can be seen thereafter with the 
presence of higher concentrations of MgSt, which could be due to the fact that at 
concentrations higher than 0.25% w/w, MgSt de-stabilizes the ordered powder formulation 
resulting in powder segregation and agglomeration. The poorest aerosol performance 
amongst the Lactochem formulations was observed with the formulation of 1.0% w/w  
MgSt, having a significant decrease in the drug deposition (ANOVA p<0.01), with a value 
of 10% less than that of the control formulation. This may be due to incomplete surface 
coverage of the lactose carrier by the MgSt upon addition of higher concentrations of MgSt 
or due to localised coverage of the carrier surface by MgSt. Therefore, instead of MgSt 
forming a continuous film on the carrier surface it may just form a film at selected areas of 
the carrier surface or may not even form a film and just agglomerate with the drug particles 
and/ or fines. When making the powder formulations, the lactose carrier was pre-blended 
with the MgSt and then this mixture was blended with the drug particles. It could be that 
during the pre-blending process the MgSt particles occupy the active sites (which are sites 
with high energy) of the carrier surface and therefore leaving the drug particles to occupy 
the passive sites of the carrier surface or existing as free or weakly bound fine particles7. 
When having 0.25% w/w MgSt, it could be that only some of the active sites are occupied, 
enabling some active sites to be occupied by the drug particles and therefore aerosolise 
upon actuation. However, if all the active sites are occupied by the MgSt particles, then the 
drug particles would have to exist as free particles or be weakly bound to the carrier surface 
or even agglomerate between them or with the fines of lactose, therefore not being able to 
penetrate into the lungs.  
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Another explanation, could be that the interparticulate interactions at the 0.25% w/w MgSt 
formulation are balanced, therefore not being too weak which would lead to the falling off 
the drug particles and forming agglomerates and not too strong which would not enable 
their detachment from the carrier surface. 
 
The Nanolac formulations were statistically significant compared to the controlled 
formulation which did not contain any MgSt. However, the best aerosol performance was 
exerted by the 0.5% w/w MgSt formulation with only 1.6% difference to the 0.25% w/w 
MgSt and both were approximately double the value of the control formulation.  
Therefore, an increasing trend can be seen starting from the controlled formulation, 
reaching the optimum concentration of 0.5% w/w MgSt which modifies adhesion and then 
decreasing at 1.0% w/w MgSt, but still being higher by 13.6% to the control formulation. 
The difference between the Nanolac and Lactochem formulations could be attributed to the 
difference in surface topography and therefore the interparticulate forces. As can be seen 
from the data, Lactochem formulations have higher aerosol performance until they reach 
the optimum concentration and then Nanolac formulations have higher aerosol 
performance.  
 
Previous studies have reported that the presence of fines increases the fine particle fraction 
through the formation of agglomerates or multiplets. Recent studies by Louey et al (2003)1 
suggest that increased lactose fines result in an agglomerated based system, resulting from 
the reduction of the free carrier space. Consequently, the fine particle fraction would 
eventually plateau and decrease due to multilayer or aggregate formation and formulation 
segregation. Therefore, looking at the data it could be that concentrations of MgSt higher 
than 0.25% w/w, the intrinsic lactose fines start to agglomerate and segregate and therefore 
decrease the fine particle fraction. 
 
Several studies have focussed on the surface roughness of carrier particles on the in vitro 
deposition pattern of the drug8,9,10.  It was shown by Heng et al (2000) 11 that an optimum 
lactose surface roughness was required for an increased fine particle fraction of salbutamol  
 84
sulfate. All these studies demonstrated that the different surface roughness of the lactose 
carrier resulted in different adhesion forces between the drug and the carrier, which was 
reflected in the in vitro deposition results. 
 
During inhalation, the adhesive forces that exist between drug and carrier particles have to 
be overcome in order to aerosolise primary drug particles. The magnitude of the separation 
forces during inhalation relative to the adhesive forces in the mixture determines the 
obtained fine particle fraction. Consequently, optimising a dry powder inhalation system 
with respect to delivered fine particle dose requires careful balancing between both types of 
forces.  This balance between the forces could possibly be reached upon the addition of 
0.25% w/w MgSt to the Lactochem formulations and 0.5% w/w MgSt to the Nanolac 
formulations and therefore a greater fine particle fraction is observed. The attachment 
forces have to be strong enough to maintain satisfactory blend homogeneity during 
handling and storage but weak enough to yield a high drug release from the carrier particles 
during inhalation. 
 
The addition of MgSt to the budesonide-Lactochem/Nanolac dry powder formulations was 
performed to investigate any effect it would have on their aerosolization performance and 
also to investigate any difference between the Nanolac and Lactochem formulations. This 
was considered to be related to the potential of lowering the adhesive interactions between 
the drug and the carrier, therefore increasing the detachment efficiency of the drug particles 
from the carrier upon aerosolization and thus improve the aerosol performance of DPI 
formulations. 
 
Magnesium stearate as suggested by other studies, should form weaker drug-lactose 
interactions within the blends by significantly modifying the adhesive and cohesive 
interactions. Within a controlled blend containing drug and lactose, it is perceived that a 
large amount of energy would be required to overcome the adhesive interaction for the 
dispersion of the drug from the lactose surface, due to the fact that there is a strong affinity 
between them compared to their cohesive forces. This should be significantly modified by 
the introduction of MgSt to the DPI formulation. 
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In the beginning of the blending process, MgSt should form a molecular film which on 
further blending would gradually build up a particulate film. The formation of a 
monomolecular film of MgSt over the excipient is due to the strong adhesive interactions 
and decreased cohesive foces between the excipient particles3. The difference in the amount 
of drug deposited in the different stages of the MSLI between the Lactochem and Nanolac 
formulations can be attributed to a number of parameters including the difference in surface 
morphology and the presence of lactose fines. 
  
As mentioned above, Lactochem having a heterogeneous surface roughness enables a range 
of weak and strong adhesive interaction between the drug particles and the carrier surface. 
Thus, particle deaggregation may occur over a wide range of energies. However, in the case 
of the Nanolac formulations, having a smooth surface enables strong interparticulate 
interactions and adhesion due to the large contact area between the drug particles and the 
carrier surface and thus a large amount of energy is required to detach them. The addition 
of MgSt, facilitates the detachment in both types of formulations via a significant reduction 
in interfacial interactions as a result of the low surface energy of the MgSt. It has been 
previously suggested that drug particles are lifted vertically off the carrier surface in dry 
powder formulations when exposed to a turbulent air flow12. Further investigations are now 
being made into whether this is actually the true mechanism13. Vainshtein et al. (1997) 14 
and Ziskind et al. (1997) 15 were some of the first groups to research the kinetic movement 
of particles removed from a surface by drag force. Transfer of turbulent energy onto a drug 
particle occurs when it is exposed to a turbulent air stream. The drug particle can be 
removed from its carrier surface when it accumulates enough energy to overcome the 
adhesion force. Vainshtein et al. 14 found that particles underwent non-linear oscillations on 
the carrier surface and the pull-off force was determined by this. In turbulent air flow the 
drag forces are greater than the lift forces and so the removal rate of the drug particles 
caused by the drag force is significantly larger than that of the lift forces. Drag forces cause 
a particle to pivot. The easiest way for a particle to be removed is for it to pivot on two of 
its contact points and to lift off the third. Once in motion the particle rolls easily off its 
pivot points. Nanolac has a smooth surface. Budesonide particles may pivot and roll off the 
Nanolac surface more easily than the Lactochem surface as Lactochem does not have as 
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smooth a surface. Lactochem particles have active sites and passive sites. Particles adhere 
more strongly to active sites such as clefts or troughs. Budesonide particles adhered to the 
Lactochem in a cleft will be hard to remove from the surface. Air cannot flow so well in 
these areas and so not enough energy is created to remove the particle. However, overall, 
budesonide particles adhere less strongly to the Lactochem surface than the Nanolac 
surface. Adhesion force is proportional to the true area of contact between particle and 
surface16. 
 
When MgSt is used in formulations, it coats the carrier surface and evens out peaks and 
troughs to create a smoother surface. It also decreases the adhesion forces as mentioned 
previously. Adding MgSt to a formulation may therefore increase the number of 
budesonide particles removed from the lactose carrier as less energy is required to remove 
them and they are freer to roll off the smoother surface. Moreover, the findings of this work 
were in accordance with the findings of the study performed by Lord et al (1996) 17 who 
found that the inclusion of lactose fines in carrier-based formulations resulted in decreasing 
adhesion between the drug particles and carrier surface, therefore requiring a small amount 
of energy to detach the drug particles leading to an increased aerosol deposition 
performance. As the data from this study suggest the Lactochem formulations which 
contained intrinsic lactose fines had a higher aerosol deposition performance from the 
control up to the 0.25% w/w MgSt formulation. This could be explained by reference to the 
work of Hersey (1975) 7 on the interactions between coarse and fine particles in the 
formation of ordered mixtures which proposed that fine particles preferentially bind to 
areas of high energy (active sites) on the surface of the carrier, leading the drug particles to 
bind to areas with lower energy.Once aerosolised, the drug particles are more easily 
detached from the surface of the carrier, increasing the proportion of drug available for 
inhalation. Therefore, carriers containing greater proportions of intrinsic lactose fines give 
better aerosol deposition performance, which can be decreased by their removal. However, 
the optimum concentration of fines for the greatest aerosol performance is unclear and 
further studies need to be conducted. 
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In addition, studies have shown that the addition of fine particles to binary mixtures of drug 
and lactose resulted in an increase in the fine particle fraction of the drug10,18,19. One of the 
reasons for the increase in fine particle fraction was the formation of multiplets of drug and 
the fine force and thus easier detachment of drug from the surface of the fine particles20. 
This could be the main reason for the best aerosolisation efficiency observed with the 
addition of 0.25% MgSt in the Lactochem formulations. 
 
In a dry powder inhaler formulation, an ideal carrier should have a suitable surface 
topography; a surface on which the adhesion forces between carrier and drug is strong 
enough for drug particles to be attached and emitted from the inhaler, yet such that a large 
proportion of the emitted dose can subsequently detach from the carrier upon inhalation20. 
Addition of fine lactose to the powder formulations may result in the formation of mono- or 
multi-layers of the fine lactose adhered to the coarse lactose, filling of surface crevices and 
saturation of the strong binding sites on the coarse lactose. Therefore, fine particles of 
lactose would be expected to reduce the interparticulate forces between the drug and the 
coarse carrier and consequently enhance the detachment of the drug from the carrier 
thereby improving the FPF of the drug21. 
 
The addition of MgSt to the formulations in theory produced a layer over the carrier and 
drug particles, as previously mentioned. When the amount of MgSt is sufficient, the 
coverage of the carrier surface with this layer is complete, therefore further reducing the 
adhesive force between the drug particles and carrier surface, increasing their detachment 
and deposition to the lungs.  
 
From the discussion above, it is clear that the interparticulate interactions between the 
various types of particles present in a carrier-based DPI formulation are critical in 
determining the overall aerosol performance. In addition, the presence of intrinsic fines in 
the carrier surface of the Lactochem played a significant role in the aerosolisation 
performance. This is explained by the ‘active site’ theory as mentioned above.  This 
hypothesis is accordance with the data by which a larger drug deposit is observed with the 
Lactochem formulations compared to the Nanolac formulations. 
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Therefore, it could be suggested that by the addition of 0.25% w/w MgSt in the Lactochem  
ormulations the interparticulate forces are balanced resulting in an optimised dry powder 
inhalation system with respect to delivered fine particle dose. However, in the Nanolac 
formulations the addition of 0.5% w/w MgSt results in balanced interparticulate forces. The 
relationship between the concentration of MgSt and aerosolisation efficiency can be 






The influence of different concentrations of MgSt on the aerosol deposition performance of 
two types of carrier based formulations was investigated. The addition of MgSt to the 
formulations has improved the aerosol deposition performance of all the formulations 
except the 1.0% w/w MgSt formulation with Lactochem which had a decreased aerosol 
deposition performance. As mentioned previously, MgSt reduces the adhesion forces 
between the drug particles and the carrier surface, facilitating their detachment and entry 
into the respiratory tract.  
 
However, excessive MgSt will decrease the adhesion forces to such an extent that there is 
virtually no interaction between the drug particles and the carrier surface and drug particles 
exist as loose agglomerates falling of the surface of the excipient and being captured at the 
early stages of the MSLI. Among the Lactochem formulations the optimum concentration 
of MgSt for the best aerosol deposition performance is 0.25% w/w since it greatly increased 
the fine particle fraction. It could be that this specific concentration of MgSt is the optimal 
for the application of a continuous thin film of MgSt around the surface, exerting an 
efficient delivery of drugs to the lungs. 
 
Among the Nanolac formulations, the 0.5% w/w MgSt formulation exerted the best aerosol 
deposition performance. This difference between Nanolac and Lactochem formulations 
could be attributed to their surface morphology. Nanolac has stronger adhesion forces 
between the drug particles and the carrier surface due to the large contact area and therefore 
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a larger amount of MgSt is required to achieve the same reduction of adhesion forces as 
with the lactochem formulations. 
Several recent patents have been registered on using MgSt in dry powder formulations such 
as by Staniforth (2002)22.This concept is being researched and developed. Chan et al. 
(2003) 23 reviewed all of the current techniques being applied to improve dry powder 
aerosol delivery. They found that the use of MgSt did improve dry powder formulations. 
The results from this study are highly significant and should be investigated further so that 
in the near future there may be a licensed dry powder inhaler formulation available which 
delivers a much higher fine particle fraction of active drug to the patient. This may mean 
that a lower dose of drug with a narrow therapeutic index will be needed to elicit a response 
in the patient than is currently used, which would mean fewer side effects for the patient. 
Dry powder inhalation formulations may be developed for systemic diseases if a high fine 
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Effects of environmental conditions on the aerosol 
deposition performance of DPI formulations 






The primary adhesion forces acting between a particle with a carrier surface in a dry 
environment i.e low relative humidity, consist of van der Waals and electrostatic forces. In 
humid environments, the condensation of water vapour leads to the introduction of a 
surface tensional force at relatively low humidity conditions leading to a meniscus type, 
capillary force at high relative humidity.1 This dynamic force has been shown to 
predominate for a number of hydrophilic and hydrophobic drug particles with a lactose 
carrier surface and significantly increasing particle adhesion3,4. 
 
Moisture uptake can directly affect the flowability of the powders and the force to detach 
the micronized particles from the carrier surface. Hence, the fine particle dose responsible 
for the pharmacological effect may be directly affected since the de-agglomeration 
properties of the powder blend will change upon storage due to moisture uptake.  
 
A number of investigations have focused on the influence of environmental conditions on 
the interparticulate interactions and subsequently on the aerosolisation performance of 
inhalation systems. Young et al. (2003)1 investigated the influence of humidity on the 
aerosolisation of three micronized drugs: disodium cromoglycate (DSCG), salbutamol 
sulphate and triamcinolone acetonide (TAA); which were stored for 12 hours at 15, 30, 45, 
60 and 75% RH. A decrease in the fine particle fraction (FPF) for both DSCG and 
salbutamol sulphate was observed with increasing humidity, suggesting that the adhesion 
properties for both drugs are predominately influenced by capillary interactions. However, 
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the FPF of TAA significantly increased as the humidity increased over the range 15% to 
75%RH, suggesting that tribology induced electrostatic forces predominated 
interparticulate interactions5. Young et al., (2004)2 also reported the effect of storage 
humidity on the aerosolisation efficiency of salbutamol sulphate produced via 
micronization and supercritical fluid (SEDS) particle engineering. It was shown that 
storage humidity had a significant effect on the aerosolisation efficiency of formulations 
comprised of both micronised and SEDS salbutamol sulphate suggesting again that 
capillary interactions play an important factor in DPI formulation performance. Jashnani et 
al.,(1995)6 have also investigated the dry powder aerosol performance of salbutamol base 
and salbutamol sulphate under different temperatures and relative humidities (20, 30 and 
45°C; 30-95% RH). The FPF for both salbutamol base and salbutamol sulphate decreased 
with increasing relative humidity at any given temperature with more profound changes 
observed at higher temperatures. Increasing temperature also resulted in diminished aerosol 
performance. 
 
With the introduction of a hydrophobic force control agent (e.g MgSt) to a carrier based 
DPI formulation, its role as a protectant from storage conditions particularly as a function 
of variations in relative humidity is a key. In addition, there is a need to define specific 
ranges of temperature and humidity for the testing of DPI formulations as well as for the 
proper storage of medication to prevent instability and degradation of the formulation. 
 
In this study, the formulations prepared in Chapter 3, with different concentrations of MgSt 
blended under shear, were tested with a MSLI upon being stored for 3 months at pre-
defined temperature and humidity, to investigate the specific role of MgSt as a hydrophobic 
agent and its concentration on aerosol deposition. The formulations were tested at three 
different environmental conditions; firstly at 25°C, 44% RH tested immediately after their 
preparation (as described in Chapter 2), and then after 3 months stored at 25°C,  75% RH 
and 40°C, 75% RH to examine how these environmental factors and time affect the aerosol 






α-Lactose monohydrate (Lactochem®) was supplied by Friesland Foods (Borculo, 
Netherlands). The lactose was vibrated through a nest of sieves to obtain 63-90 μm sieve 
fraction, which was used throughout the study. Micronised budesonide was supplied by 
Sicor (Batch no. 6157/M1, Santhia, Italy). Ten percent etched lactose (Nanolac) was 
produced according to the procedure described in Chapter 3, Section 3.3.3 outlined by El-
Sabawi et al. (2006)7. Magnesium stearate was supplied by Fisher chemicals (Batch no. 
9880836, Loughborough, UK). The acetonitrile and methanol were of HPLC grade and 
were obtained from Fisher Scientific (Loughborough, UK). Water was purified by reverse 
osmosis (MilliQ, Millipore, Molsheim, France). Hydroxypropyl methylcellulose (HPMC) 
capsules (size 3) were supplied by Qualicaps (Batch no. EO404632, Shiongi Qualicaps, 
Madrid, Spain). Potassium carbonate anhydrous was supplied by Acros Organics (Batch 
no. A018189301, New Jersey, USA) for use as a humidifier. Ceramic balls of 10mm 





4.3.1 Scanning electron microscopy 
 
 




4.3.2 Particle size analysis of aerosol cloud 
 
 
The particle size distribution of the aerosol cloud emitted from a Cyclohaler® by each of the 
formulations described in Chapter 3 following storage for 3 months at 25°C, 75%RH and 
40°C, 75% RH were determined using a HELOS laser diffraction sensor and INHALER 
adapter (both from Sympatec GmbH, Clausthal-Zellerfeld, Germany). The flow rate 
through the INHALER module was set at 60 L/min and the mouthpiece of the Cyclohaler® 
was fitted directly into the measuring chamber, to enable measurement of the particle size 
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distribution of the aerosol cloud immediately after emission. For each measurement, a size 
3 HPMC capsule filled with 25 ± 1mg of the test formulation was inserted in to the 
Cyclohaler®, opened by piercing the capsule and its contents aerosolised through the laser 
of the diffraction sensor for 10 seconds. Particle size analysis was carried out using 
WINDOX 4.0 software (Sympatec GmbH, Clausthal-Zellerfeld, Germany). Particles size 
distributions and values presented are the average of 5 determinations. 
 
 
4.3.3 In vitro aerosolisation studies 
 
 
HPMC capsules, size 3, were filled with 25 ± 3 mg of the powder blends prepared as 
described in section 3.4.4. Ninety capsules were filled for each concentration of the blends 
from the same powder blend. A series of both long term and accelerated stability studies 
were performed. Ninety capsules of each formulation were stored in a sealed container at a 
relative humidity of 75% RH (prepared using saturated solution of sodium chloride7) at 
40°C and of 75% RH at 25°C respectively, within temperature controlled ovens for 3 
months.  
 
The in vitro inhalation performance of budesonide from each blend was assessed using a  
MSLI (Copley Instruments Ltd, Nottingham, UK) as discussed in chapter 2, Section 2.2.3. 
 
4.3.4 Analysis of budesonide  
The budesonide was analysed using high performance liquid chromatography (HPLC), as 
discussed in Chapter 2, Section 2.2.5.1. 
 
4.3.5 Optical imaging of powder samples 
 
 
Digital optical images of samples of powder samples were taken using a digital camera 
(Samsung, China) after being stored for three months at the various environmental 
conditions (25°C/44%RH, 25°C/75%RH, 40°C/75%RH) investigated throughout the study. 
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4.3.6 Statistical analysis 
 
 
Statistical analysis of the data was carried out using Minitab for Windows. One-way 
ANOVA (analysis of variance) was used to determine the variance of data. Fisher’s pair-
wise analysis was carried out to determine where those differences were. Statistical 
significance was defined as either P<0.05 or P<0.01. The levels of significance obtained are 
indicated in the key on individual graphs. 
 
 
4.4 Results and Discussion 
 
4.4.1 Scanning electron microscopy 
 
 
Scanning electron microscopy images of the various blends upon storage at elevated 
temperature and/or relative humidity are show in figures 4.1-4.8. The SEMs showed a 
considerable degree of powder clustering and agglomeration at high humidities with 
significant agglomeration at the highest humidity used in this study (40°C, 75%RH). The 
Lactochem formulations showed a more pronounce agglomerations than the Nanolac 
formulations. Such physical interaction and agglomeration may be an indication of a 
considerable increase in inter-particle adhesion arising from the condensation of water 
vapour at high RH levels, as a consequence promoting the formation of a capillary meniscus 
around the contact points of contiguous surfaces. A similar behaviour was observed at 25°C, 
75%RH, although the degree of agglomeration may have been less. 
 The agglomeration was more profound for the Lactochem formulations than the Nanolac 
formulations when stored at 25°C, 75%RH. However, both types of formulations exhibited a 
high degree of agglomeration when stored at 40°C, 75%RH. The SEMs of the Lactochem 
formulations at 40°C, 75%RH show respirable sized drug particles adhering to a larger, 
excipient particles whereas the Nanolac formulations show a number of agglomerates of 
respirable sized  particles.  
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A) B) 
Figure 4.1 Representative scanning electron micrographs showing the control 
formulation at 25°C, 75%RH containing Lactochem and budesonide at A) x1200 and B) 
x2200 magnifications. 
 
    
A)  B) 
Figure 4.2 Representative scanning electron micrographs showing the control 
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C) 
 
Figure 4.3 Representative scanning electron micrographs of the formulations containing  
Lactochem and budesonide pre-conditioned with A) 0.25%, B) 0.5% and C) 1.0% w/w  
MgSt at 25°C, 75%RH. 
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Figure 4.4 Representative scanning electron micrographs of the formulations containing  
Nanolac and budesonide pre-conditioned with A) 0.25%, B) 0.5% and C) 1.0% w/w MgSt  
at 25°C, 75%RH. 
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Figure 4.5 Representative scanning electron micrographs showing the control 
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Figure 4.6 Representative scanning electron micrographs showing the control 
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Figure 4.7 Representative scanning electron micrographs of the formulations containing  
Lactochem and budesonide pre-conditioned with A) 0.25%, B) 0.5%, C ) 1.0% w/w MgSt  
at 40°C, 75%RH. 




     
 
     
C) 
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Figure 4.8 Representative scanning electron micrographs of the formulations containing 




4.4.2 Particle size analysis 
 
 
fference in the coarse particle size measurements d50 and d90 can be seen 
ith storage. However, these data suggest that there is an influence on the smaller particle 
pon introducing 0.25% w/w MgSt to the Lactochem and 
anolac formulations there was a decrease of 50% of the fines. In addition, the number of 
eter of < 5 μm were doubled upon introducing the 0.25% w/w MgSt, 
ation. 
The particle size distribution of the Lactochem and Nanolac formulations upon storage at 
25C, 75% RH are shown in tables 4.1 and 4.2 respectively. As shown in the tables below, 
no significant di
w
size measurements (d10) as u
N
particles with a diam
while the number of particles with a diameter < 10 μm was also increased. While for the 
0.5 % and 1.0% MgSt and Lactochem formulations the d10 values and particles < 5 μm 
were almost the same as the control formulations, with the Nanolac formulations the d10 
values for all the concentrations of MgSt were significantly lower than the control Nanolac 
formulation and the particles < 5 μm were significantly higher than the control formul
It is also interesting to note in table 4.2, that with the Nanolac formulation upon increasing 
the concentration of MgSt, the d10 particles are decreased while the particles < 5 μm are 
increased. The data could suggest that by using the Nanolac lactose, more fines with a 










Table 4.1 Particle size distribution statistics summary of the Lactochem formulations at  
25°C, 75%RH. 
Materials 
At 25°C, 75%RH 
d10 
(μm ± SD) 
d50 
(μm ± SD) 
d90 
(μm ± SD) 
% < 10 μm 
(μm ± SD) 
% < 5 μm 










4.77±1.63 62.63±9.05 122.83±2.63 19.58±7.12 12.05
0.5% M
Lactochem+budesonide 
8.05±1.61 69.38±9.36 117.31±8.70 12.49±1.91 6.47±1.17 gSt + 
1.0% MgSt + 
Lactoc nide 




Table 4.2 Particle size distribution statistics summary of the Nanolac formulations at  
5%RH 




At 25°C, 7 (μm ± SD) (μm ± SD) (μm ± SD) (μm ± SD) (μm ± SD) 
Nanolac+budesonide  
 
45.43±4.26 89.92±1.84 130.14±3.44 5.46±0.79 3.91±0.53 
0.25% MgSt + Nanolac 
 +budeso




27.09±3.59 89.18±1.41 127.60±2.97 9.42±1.70 7.02±1.30 gSt + Nanolac  
1.0% MgSt + Nanolac  
+budes














The particle size distribution of the Lactochem and Nanolac formulatios upon storage at   
0°C, 75%RH, have similar findings as with the formulations stored at 25°C, 75%RH. As 
an be seen in table 4.3, the addition of 0.25% w/w MgSt to the Lactochem formulation, 
ecreases the value of d10 and significantly increases the particles < 5 μm. However, a 
ifferent effect was observed for the Nanolac formulations upon storage at 40°C, 75%RH 




 5 μm 






the lowest value upon addition of 0.5% MgSt, which then slightly increases at 1.0% MgSt.
The particles < 5 μm are slightly increased upon addition of 0.25% MgSt, reaching the 
highest value at 0.5% MgSt and then decreases again upon addition of 1.0% MgSt. 
 
  
Table 4.3 Particle size distribution statistics summary of the Lactochem formulations at  




(μm ± SD) 
d50 
(μm ± SD) 
d90 
(μm ± SD) 
% < 10 μm 




2.88±0.32 em+budesonide 13.15±1.78 63.12±7.10 145.06±5.21 7.42±0.87 
0.25%MgSt+Lactochem 
+budesonide 
9.91±3.92 58.42±9.87 111.34±5.74 11.61±1.43 8.80±1.31 
0.5% M
+budeso




9.79±2.66 70.02±5.61 128.79±9.65 10.88±2.12 4.75±0.84  
onide 
 
Table 4.4 Particle size distribution statistics summary of the Nanolac formulations at 
40°C, 75%RH. 
 
d  Materials 
At 40°C, 75%RH 
d  10
) 
50 90 % < 10 
(μm ± SD (μm ± SD) 
d  
(μm ± SD) 
μm 
(μm ± SD) 
% < 5 μm 
(μm ± SD) 
Nanolac+bude
 
sonide  51.55±2.83 91.23±2.66 140.67±2.88 1.89±0.63 1.31±0.48 
0.25% MgSt + Nanolac 
 +budeso




34.03±3.39 91.65±1.32 137.64±1.19 7.71±1.42 5.70±1.09 gSt + Nanolac  
1.0% MgSt + Nanolac  
+budes





C) D) F)  
4.4.3 In vitro aer tud
.1 The influence of storage conditions on the in vitro aerolisation performance 
 an orm
hown in Figure 4.9a of the stage-by-stag eposition within the MSLI there is an 
increase in the capsules/device retention and upper stages of the impinger upon storage, 
ating a relative decrease in am t of the dose actually entering the lower stages of 
the MSLI. The retention of drug in the capsules and device and upper stages of the MSLI 
may be due to the increased cohesiveness and adhesiveness of the drug upon storage at 
elevated temperature and humidity, reducing the detachment of the drug particles from 
the carrier surface. This increase in interparticulate interaction could be due to the 
increase in capillary forces which arises from the condensation of the increasingly 
adsorbed water vapour layers onto the surface at high RH levels and promoting the 
formation of a capillary meniscus around the contact points of contiguous 
surfaces2.Another possible explanation could be the re-crystallization of amorphous 
domains at conditions of elevated RH levels leading to irreversible aggregation through 
solid bridge formation which can affect aerosol generation and lung deposition 
performance8,9.There was no significant statistical difference between the amount of drug 
deposited at the capsules and device stage between the different environmental 
conditions. However, there was a significant increase (ANOVA p<0.05) in the amount of 
drug deposited at the throat and stage 1 upon storage at 25°C, 75%RH compared to the 
formulation stored at 25°C, 44%RH, with a larger significant increase (ANOVA p<0.01) 
upon storage of the formulation at 40°C, 75%RH. No significant difference was observed 
on the amount of drug deposited at stages 2 and 3 of the MSLI apparatus between the 
different environmental conditions. However, there was a significant reduction (ANOVA 
p<0.05)of the drug deposition at stage 4 upon storage at 25°C, 75%RH compared to the 
amount of drug deposited by the formulation stored at 25°C, 44%RH. The significant 
decrease (ANOVA p<0.01) in the amount of drug deposited in stage 4 upon storage at 
40°C, 75%RH was half the value of the amount of drug deposited by the formulation 
stored at 25°C, 44%RH. This was due to the fact that most of the drug was captured at 
osolisation s ies 
 
4.4.3
of Lactochem d Nanolac f ulations. 
 
As s e d
indic oun
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the initial stages of the MSLI apparatus with huge losses in the capsules and device stage 
nd throat and s1 stage. The formulations at both environmental conditions (25°C, 
pared to the formulation stored at the 
mbient conditions. The drug deposition was remarkably reduced to the 1/5th of the 
he 
a
75%RH and 40°C, 75%RH) exerted a significant decrease (ANOVA p<0.01) in the drug 
deposition in the filter stage of the MSLI com
a
amount of drug deposited by the formulation stored at ambient conditions. Therefore, t
data suggests that the environmental conditions have greatly influenced the aerosol 
deposition performance of the Lactochem control formulation. 
 
Lactochem+budesonide





















   
   
   



























  Figure 4.9a The deposition of budesonide, as a percentage of recovered dose  
  throughout the MSLI for the Lactochem control formulations at the different  
 environmental conditions.  
 (Mean ± S.D, n=3,  *P<0.05, ** P<0.01: significant difference compared to the     
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Figure 4.9b The deposition of budesonide, as a percentage of recovered dose, 
throughout the MSLI for the Nanolac control formulation at the different 
environmental conditions. (Mean ± S.D, n=3, 
*
*P<0.05, ** P<0.01: significant 
difference compared to the  ambient conditions by ANOVA one-way. C & D: 




 environmental conditions was significantly higher (ANOVA 
tively, 
RH. These data 
ggested that the environmental conditions significantly affected the drug deposition in 
e capsules and device. The increase in drug deposition in the capsules and device stage 
Figures 4.9a and 4.9b show the stage-by stage deposition profile of the Lactochem
Nanolac formulations respectively upon storage. The drug retention in the capsule/
upon storage at both elevated
p<0.01) than the control, with a 15% and 35% increase in the drug deposited, respec




may subsequently lead to a small drug deposition in the following stages of the MSLI. 
Interestingly, upon storage of the formulation at 40°C, 75%RH the amount of drug 
deposited in the throat and stage 1 was significantly reduced (ANOVA p<0.01), compared 
to the amount of drug deposited by the formulation stored at the ambient conditions, while 
no significant difference was observed upon storage of the formulation at 25°C, 
75%RH.The amount of drug deposited in stage 2 upon storage of the formulations at the 
elevated conditions was significantly reduced (ANOVA p<0.01) to half the value of that of 
the formulation stored at the ambient conditions. In stage 3 and stage 4, only the storage of 
the formulation at 40°C, 75%RH resulted in a significantly lower drug deposition 
(ANOVA p<0.05).Upon storage of the formulations at both elevated conditions, the 












   
   
   













































Figure 4.10a The deposition of budesonide, as a percentage of recovered dose, 
throughout the MSLI for the 0.25% w/w MgSt+Lactochem+budesonide formulation 
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at the different environmental conditions. (Mean ± S.D, n=3, *P<0.05, ** P<0.01: 
significant difference compared to the ambient conditions by ANOVA one-way. C





















   
   
   
   






































Figure 4.10b The deposition of budesonide, as a percentage of recovered dose, 
throughout the MSLI for the 0.25% w/w MgSt+Nanolac +budesonide formulation at  
the different environmental conditions. (Mean ± S.D, n=3, *P<0.05, ** P<0.01: 
significant difference compared to the ambient conditions by ANOVA one-way. C & 









4.4.3.2 The influence of storage conditions on the in vitro aerolisation
performance of 0.25% w/w MgSt formulations 
 
he addition of 0.25% w/w MgSt to the Lactochem and budesonide formulation, the 
mount of drug deposited in the capsules and device stage was reduced upon storage at 
5°C, 75%RH and 40°C, 75%RH compared to the same formulation stored at 25°C, 
44%RH. However, the reduction of the amount of drug deposited was not statistically 
significant. In addition, a smaller amount of drug remains in the capsule and device 
compared to the Lactochem control formulation, indicating that a higher emitted dose 
of the drug via the addition of MgSt. A significant increase (ANOVA p<0.05) in the 
amount of drug deposited in the throat and stage 1 upon storage of the formulation at 
25°C, 75%RH was measured to with respect to the storage of the 0.25% MgSt 
formulation at 25°C, 44%RH. A further significant increase (ANOVA p<0.01) in the 
amount deposited that the upper stage was observed upon storage of the formulation at 
40°C, 75%RH. A significant increase (ANOVA p<0.05) in the amount of drug 
deposited in stage 2 was also determined for the storage at 25°C, 75%RH compared to 
the formulation stored at 25°C, 44%RH. There was no significant difference upon 
storage of the formulation at 40°C, 75%RH.Upon storage of the formulation at 40°C, 
75%RH, the amount of drug deposited in stages 3 and 4 of the MSLI was significantly 
reduced (ANOVA p<0.01), while the amount of drug deposited by the formulation 
stored at 25°C, 75%RH exhibited no significant difference. The amount of drug 
eposited in the filter stage of the MSLI from the formulations stored at elevated 
anolac and budesonide, the amount of drug deposited in the 
apsules and device stage upon storage of the formulation at 25°C, 75%RH was 
gnificantly lower (ANOVA p<0.05), compared to the formulation stored at 25°C, 
4%RH, (tables 4.5-4.6) which was further significantly reduced (ANOVA p<0.01) 






environmental conditions was significantly reduced (ANOVA p<0.01) compared to the 
amount of drug deposited in the filter stage by the formulation stored at 25°C, 44%RH. 
 
As shown in figures 4.10a and 4.10b for the stage-by-stage deposition of the addition 






25°C, 44%RH. These data suggest that upon storage of the formulations at the elevated 
 entering the 
as observed in the drug deposited in 
e 
 at 
ge 2 of 




onditions. There was no significant difference between the formulation stored at 
t to 
 
environmental conditions more drug is leaving the capsules and device and
MSLI apparatus. While no significant difference w
the throat and stage 1 upon storage at 25°C, 75%RH, a significant increase (ANOVA 
p<0.01) was observed upon storage at 40°C, 75%RH, (tables 4.7-4.8) to a value twice 
that of the formulation stored at the ambient conditions. Hence, at 40°C, 75%RH ther
is a significant retention of drug particles to the carrier particles and thus suggesting 
either a considerable adhesion or the formation of solid bridges to the carrier surface
elevated temperature. Considering the significant difference between the retention on 
the upper stages of the MSLI for the 25°C, 75%RH and 44°C, 75%RH formulations, 
these data suggest that temperature may have a key influence on its variability. Upon 
storage of the formulation at 40°C, 75%RH, the amount of drug deposited in sta
the MSLI was significantly higher (ANOVA p<0.01) to the amount of drug deposited 
by the formulation stored at ambient conditions, while upon storage at 25°C, 75%RH 
no significant difference was observed. No significant differences were observed
amount of drug deposited in stage 3 of the MSLI between the formulations at the 
different environmental conditions. In stage 4, the amount of drug deposited by the
formulation stored at 40°C, 75%RH was significantly lower (ANOVA p<0.01) 
compared to the amount of drug deposited by the formulation stored at 25°C,44%RH, 
while there was no significant difference with the formulation stored at 25°C, 75%R
This was expected, as the drug retention in the upper stages was greater for the 
formulation stored at 40°C, 75%RH. Upon storage of the formulation at 40°C, 75%
the amount of drug deposited in the filter stage was significantly reduced (ANOVA 
p<0.01) to the amount of drug deposited by the formulation stored at the ambient 
c
ambient conditions and at 25°C, 75%RH. The set conditions of 25°C, 75%RH did not 
have an influence on the aerosolisation performance of this formulation since the 
amount of drug deposited in each of the MSLI stages was not significant differen
the amount of drug deposited by the formulation stored at ambient conditions. 
However, upon storage of this formulation at 40°C, 75 % RH resulted in a significant
decrease in aerosolisation performance. 
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4.4.3.3 The influence of storage conditions on the in vitro aerolisation 
performance of 0.5% w/w MgSt formulations 
 
As shown in figure 4.11a, upon storage of the 0.5% w/w MgSt Lactochem formulation
at 40°C, 75%RH the amount of drug deposited in the capsules and device stage was 
significantly reduced (ANOVA p<0.05), while no significant difference was observed 
in the drug deposition of the formulation stored at 25°C, 75%RH. In this case, the 
storage of the formulation at 40°C, 75%RH resulted in less drug remaining in the 
capsules and device and more drug entering the following stages of the MSLI. 
Therefore the increased humidity and temperature had a positive influence on drug 
retention in the capsules and device stage of this formulation. One possible cause may
be due to the formation of agglomerates caused by considerable increase in inter-
particle adhesion due to capillary interaction. Upon storage of the formulation at 25°C,
75%RH, the amount of drug deposited in the throat and stage 1 of the MSLI was 
significantly reduced (ANOVA p<0.05), while the amount of drug deposited by the 
formulation stored at 40°C, 75%RH was not significantly different to the amount o
drug deposited by the formulation stored at the ambient conditions. No significant 
difference in the amount of drug deposited in stage 2 was observed upon storage
formulations at the elevated environmental conditions. Furthermore, the amount of 
drug deposited in stage 3 of the MSLI upon storage at elevated conditions was 
significantly higher (ANOVA p<0.05) than the amount of drug deposited upon s
at 25°C,44%RH, resulting in a larger amount of drug reaching the lower stages of the 
MSLI and therefore the lower airways in the RT. The amount of drug deposited in 
stage 4 of the MSLI upon storage of the formulations at the elevated conditions wa
significantly different to the amount of drug deposited by the formulation stored at
25°C, 44%RH. Upon storage of the formulation at 25°C, 75%RH, the amount of drug 
deposited in the filter stage was significantly lower (ANOVA p<0.05) than the am
of drug deposited by the formulation stored at the ambient conditions, while the 
amount of drug deposited by the formulation stored at 40°C, 75%RH was not 
























As shown in figure 4.11b for the addition of 0.5%w/w MgSt-Nanolac formulation the 
amount of drug deposited in the capsule and device stage upon storage at both elevate
environmental conditions was not significantly different to the amount of drug 
deposited by the formulation stored at the ambient conditions. Upon storage of the 
formulation at 40°C, 75%RH the amount of drug deposited in the throat and stage 
the MSLI was significantly increased (ANOVA p<0.05) compared to the amou
drug deposited by the formulation stored at 25°C, 44%RH. The amount of drug in th
upper stages upon storage at 25°C, 75%RH was not significantly different to the 
amount of drug deposited by the formulation stored at the ambient conditions. The 
amount of drug deposited in stage 2 and stage 3 of the MSLI upon storage at both 
elevated environmental conditions was not significantly different to the amount of
deposited by the formulation stored at the ambient conditions. The amount of drug 
deposited in stage 4 of the MSLI for the 25°C, 75%RH was significantly higher 
(ANOVA p<0.05) than the amount of drug deposited by the formulation stored at 
25°C, 44%RH, while the formulation stored at 40°C, 75%RH showed no significant 
difference. In the filter stage, no significant difference was observed in the amount o
drug deposited between the formulations stored at the different environmental 
conditions. These data suggested that environmental conditions do not affect the 
aerosolisation performance of the 0.5% w/w MgSt formulation. The reason could be 
the formation of the hydrophobic layer of MgSt over the whole surface of the carrie
providing an interfacial barrier and thereby limiting the influence of elevated 
conditions of relative humidity. The same results were observed with the Lactochem
formulations as discussed previously; the addition of 0.5% w/w MgSt provided 






























   
   
   
   


























Figure 4.11a The deposition of budesonide, as a percentage of recovered dose,  
throughout the MSLI for the 0.5% w/w MgSt+Lactochem+budesonide formulation 
the different environmental conditions. (Mean ± S.D, n=3, 
at  
*P<0.05, ** P<0.01:  
significant difference compared to the ambient conditions by ANOVA one-w



































   
   
   

























Figure 4.11b The deposition of budesonide, as a percentage of recovered dose,  
throughout the MSLI for the 0.5% w/w MgSt+Nanolac +budesonide formulation at  
t environmental conditions. (Mean ± S.D, n=3, *P<0.05, **the differen P<0.01:  
 
 MgSt formulations 
he drug deposition of the 1.0% w/w MgSt-Lactochem formulation in the capsules and 
evice stage varied at the different environmental conditions as shown in figure 4.12a. 
pon storage at 25°C, 75%RH there was no significant difference in the amount of 
rug deposited in the capsules and device compared to the drug deposited by the 
rmulation stored at the ambient conditions. However upon storage at 40°C, 75%RH, 
significant difference compared to the ambient conditions by ANOVA one-way. C &  
D: capsules & device) 
4.4.3.4 The influence of storage conditions on the in vitro aerolisation 








the drug retention was significantly higher (ANOVA p<0.01). The retention was 
approximately double that of the formulation stored at ambient conditions. 
Interestingly, the drug retention in the capsules and device was not influenced by the 
storing at 25°C, 75%RH. The direct influence of temperature further suggests the 
possible formation of solid crystal bridges at these elevated conditions. There was no 
significant difference in the drug deposited in the throat and stage1 of the MSLI 
apparatus between the formulations stored at the different environmental conditions. 
The drug deposited in stage 2 of the MSLI, was significantly lower (ANOVA p<0.05) 
upon storage of the formulation at 40° C, 75%RH, while no significant difference was 
observed with the formulation stored at 25°C, 75%RH compared to the formulation 
stored at ambient conditions. 
 
Storage of the formulations at different environmental conditions had no significant 
influence on the amount of drug deposited on stage 3 of the MSLI apparatus. There 
was a significant decrease of 50% in the drug deposited in stage 4 (ANOVA p<0.01) 




formulation stored at 25°C, 75%RH. .The drug deposition in the filter stage of the 
MSLI apparatus of the formulations stored at both elevated conditions were 















1% w/w MgSt+Lactochem+budesonide 










   
   
   









































igure 4.12a The deposition of budesonide, as a percentage of recovered dose,  
roughout the MSLI for the 1.0% w/w MgSt+Lactochem+budesonide formulation at  
t environmental conditions. (Mean ± S.D, n=3, 
F
th
*P<0.05, **the differen P<0.01:  
icant difference compared to the ambient conditions by ANOVA one-way. C &  signif

























   
   
   
































Figure 4.12b The deposition of budesonide, as a percentage of recovered dose,  
throughout the MSLI for the 1.0% w/w MgSt+Nanolac +budesonide formulation at  
e different environmental conditions. (Mean ± S.D, n=3, *P<0.05, **th P<0.01:  
C &  
e formulation at 25°C, 75%RH was significantly higher 
NOVA p<0.05) than the control formulation stored at 25°C, 44%RH. An even 
greater significant increase (ANOVA p<0.01) in the amount of drug deposited was 
observed upon storage of the formulation at 40°C, 75%RH having a value double that 
of the formulation stored at ambient conditions. Upon storage of the formulation at 
40°C, 75%RH the amount of drug deposited in the throat and stage 1 was significantly 
lower (ANOVA p<0.05) compared to the amount of drug deposited by the formulation 
stored at 25°C, 44%RH, while no significant difference was observed upon storage at 
significant difference compared to the ambient conditions by ANOVA one-way. 
D: capsules & device) 
 
As shown in figure 4.12b, the amount of drug deposited in the capsules and device 




25°C, 75%RH. The amount of drug deposited in stage 2 of the MSLI was significantly 
lower (ANOVA p<0.01) upon storage of the formulations at both elevated 
environmental conditions compared to the amount of drug deposited upon storage at 
ambient conditions. Upon storage of the formulation at 40°C, 75%RH the amount of 
drug deposited in stages 3 and 4 of the MSLI was significantly lower (ANOVA 
p<0.01) to a value approximately a third of the formulation stored at ambient 
conditions, while there was no significant difference upon storage at 25°C, 75%RH. 
The amount of drug deposited in the filter stage of the MSLI was significantly lower 
(ANOVA p<0.01) for the formulations stored at the elevated environmental conditions, 
than the formulation stored at ambient conditions. Thus, storage of the formulation at 
40°C, 75%RH led to a dramatic decrease in aerolisation performance and indicating the 






Table 4.5 The deposition of budesonide as mean drug weight per shot (μg) at 25°C, 75%RH in the different stages of the  MSLI   
for  the Lactochem formulations and standard deviations (Mean ± SD), n=3. 
                  (Mean ± SD) 
                        (μg) 













Lactochem+ budesonide 53.0±10.8 13.1±1.9 49.7±7.2 15.2±3.1 8.8±1.3 9.0±0.1 0.6±0.2 
0.25% w/w MgSt + 
Lactochem+budesonide 
29.3±6.6 7.3±0.9 31.8±2.0 10.9±1.9 13.2±2.3 19.2±2.5 7.1±1.3 
0.5% w/w MgSt + 
Lactochem+budesonide 
45.2±10.7 8.7±0.3 37.0±4.4 13.7±2.3 17.6±3.7 18.6±1.9 6.7±1.4 
1% w/w MgSt + 
Lactochem+budesonide 
21.3±8.7 12.9±1.5 67.5±7.7 18.7±3.6 9.9±2.3 8.3±0.9 1.5±0.3 
 
Table 4.6 The deposition of budesonide as mean drug weight per shot (μg) at 25°C, 75
for the Nanolac formulations and standard deviations (Mean ± SD), n=3. 
                  (Mean ± SD) 
                        (μg) 














Nanolac + budesonide 31.8±8.7 5.0±1.3 86.6±3.3 4.2±0.2 5.5±0.9 6.0±1.2 1.2±0.3 
0.25% w/w MgSt + 
Nanolac+budesonide 
52.6±5.4 5.1±1.1 30.1±12.9 5.4±0.8 11.4±0.5 20.4±1.0 10.1±3.4 
0.5% w/w MgSt + 
Nanolac+budesonide 
42.0±8.4 5.3±0.7 35.7±3.54 8.1±1.7 15.2±3.0 28.7±5.5 10.5±2.2 
1% w/w MgSt + 
Nanolac+budesonide 
44.9±5.2 3.0±1.0 35.5±5.9 5.2±1.0 7.1±1.9 11.2±3.7 6.8±1.2 
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Table 4.7 The deposition of budesonide as mean drug weight per shot (μg) at 40°C, 75%RH in the different stages of the  MSLI   










s4 filter                   (Mean ±
) 
 SD) 
                        (μg





Lactochem+ budesonide 52.9±6.1 15.4±2.5 3 7   2 45.7±9. 12.5±0. 9.3±0.6 5.1±0.9 0.7±0.




39.8±9.3 8.3±1.8 9.2±1.2 11.8±0.4 3.1±0.6 
0.5% w/w MgSt + 
sonide Lactochem+bude
21.7±2.3 11.5±1.9 50.2±4.1 15.1±4.2 17.0±2.7 24.6±2.4 7.8±1.2 
1% w/w MgSt + 
Lactochem+budesonide 
57.9±12.8 8.5±1.1 62.5±12.6 12.9±2.2 6.0±1.3 4.2±1.1 0.6±0.1 
 
 
Table 4.8 The deposition of budesonide as mean drug weight per shot (μg) at 40 °C, 75%RH in the different stages of the  MSLI  
for the Nanolac formulations and standard deviations (Mean ± SD),n=3. 
 
)                   (Mean ± SD
                        (μg) 













Nanolac + budesonide  54.9±3.1 3.0±0.7 60.8±10.0 2.2±0.6 2.6±0.4 3.1±0.6 0.6±0.1 
0.25% w/w MgSt + 
nide Nanolac+budeso
27.9±2.0 3.4±0.4 71.6±14.3 7.3±1.3 10.1±1.9 11.8±0.3 3.3±0.7 
0.5% w/w MgSt + 
Nanolac+budesonide 
38.9±5.2 4.9±0.6 43.2±5.2 7.6±0.8 14.8±3.3 25.8±4.7 9.4±4.3 
1% w/w MgSt + 
Nanolac+budesonide 
94.7±4.5 1.3±0.1 37.3±10.7 2.9±0.9 2.6±0.5 4.4±0.9 1.1±0.3 
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  4.4.4 Summary of deposition performance of the formulations upon storage at different conditions 
                  (Mean ± SD) Recovered Dose 
 (μg) 
Emitted Dose  
(μg) 







Table 4.9     Table 4.10 The deposition of budesonide in the MSLI from the Lactochem formulations at 25°C, 75%RH via a 
Cyclohaler (Mean   ±  S.D, n=3).  
 
                     
H At 25°C, 75%R
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140 2.0 18.9±14.1 19.7±3.2 14 0 16 7 
    
Table 4.10 The deposition of budesonide in the MSLI from the Nanolac formulations at 25°C, 75%RH via a Cyclohaler (Mean  
At 25°C, 75%RH  (μg) (μg) 







  ±  S.D, n=3). 
                  (Mean ± SD) 





Nanolac + budesonide 140.3±12.0 108.6±3.9 12 2.1 9.1±1.3 11.7±1.6 
 
.7±
0.25% w/w MgSt + 
e 
135.2±18.1 82.5±15.1 41.9±2.0 31.4±4.1 51.9±9.3 
Nanolac+budesonid




5.5±1 1 3 .2±4 .3±4.14 0.0 03.5±11.9 54.4±10. 37 .8 52 6 
1% w/w MgSt + 
Nanolac+budesonide 














   Table 4.11 The deposition of budesonide in the MSLI from the Lactochem formulations at 40°C, 75%RH via a Cyclohaler
   (Mean ± S.D, n=3). 
 
(Mean ± SD) 
 
At 40°C, 75%RH 
Recovered Dose Emitted dose Fine particle dose FP FP
Lactochem+ budesonide 141.6±7.9 88.7±9.7 15.1±1.0 
 
10.7±1.1 17.2±2.8 
0.25% w/w MgSt + 
esonidLactochem+bud e 
24.1±1.1 22.7±1.4 31.1±3.7 106.9±10.1 78.54±11.4 
0.5% w/w MgSt + 
desonidLactochem+bu e 
50.1±12.1 34.4±4.4 47.0±3.4 147.7±14.9 126.0±14.4 
1% w/w MgSt + 
Lactochem+budesonide 
144.3±15.4 50.0±11.8 8.1±1.6 5.6±1.0 16.8±4.1 
 
The deposition of budesonide in the MSLI from the Nanolac formulations at 40°C, 75%RH via a Cyclohaler (Mean       Table 4.12 
     ± S











                  (M
                     





Nanolac + budesonide 127.2±7.9 72.3±8.0 6.3±1.2 5.0±1.1 8.9±2.4 
 
0.25% w/w MgSt + 
Nanolac+budesonide 
106.9±10.1 78.5±11.4 24.1±1.1 22.7±1.4 31.1±3.7 
0.5% w/w MgSt + 
Nanolac+budesonide 
147.7±14.8 126.0±14.1 49.3±5.6 33.4±2.7 39.2±2.6 
1% w/w MgSt + 
Nanolac+budesonide 
152.6±1.2 94.7±13.8 10.8±1.5 7.0±0.9 11.5±2.5 
 
The environmental conditions under which the form tions were stored significantly 
affected the recovered dose of the Lactochem form ons as shown in figure 4.13a. This 
coul  due to t form  g er  as s sted b he S  a he ic
imag pon st f L ch co l for tion C th a
slight decrease in recovered dose but not significantly different compared to the 
form ion stored at 25°C, 44%RH. A significant 12.5% decrease (ANOVA p<0.05) in 
reco d dose w e  u  s ge he f
w/w MgSt form  e it  s ic redu  upo g bo le d
conditions of temperature and humidity, with the dose recovery being half that of the 
form ion at a ent conditions (ANOVA p<0.01). Upon storage of the 0.5% w/w MgSt 
form ion at e ted e o nt n
reco d dose e th rm tio ored mbient condi , ca  t
the environmental conditions did not affect the recovered dose of this formulation. The 
1.0% w/w MgSt formulation stored at 25°C, 75%RH showed a significant reduction 
(ANOVA p<0.01) in recovered dose compared to the formu n stored at 25°C, 44%RH. 
Upo  storage C th o d do as a
(ANOVA p<0.05) but to a lesser amount than the f ulati d 5 75 H
 
The recovered doses of the Nanolac formulations with and without MgSt are shown in 
Figure 4.13b. It is evident that re r ose o  Na c con  f
stora t elevat ironmental co ions signif tly in d, r h
Lactochem cont orm on er n ntly ease his d re co b
attributed to possible difference in surface morphology and the degree of processed induced 
disorder. Upon storage of the Nanolac control formulation at 25°C, 75%RH the recovered 
dose was significantly increased by 30% (ANOVA p<0.01) while the recovered dose of the 
form ion upo r 0 g antly reas y A
p<0. ev ad /w St th  w n  
29% ere s V  ted m
reco se of the at b e  
decr OVA p<0.0 in recovered dose was o









































































ditions, there was only a slight decrease in 
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MgSt formulation upon storage at 25°C, 75%RH significantly increased (ANOVA p<0.05) 
with a further increase in recovered dose observed upon storage of the formulation at 40°C








































Figure 4.13a A graph showing the relationship between the recovered dose and the  
Lactochem formulations at the different environmental conditions.  (Mean ± SD,  
n=3)( *P<0.05, ** P<0.01: significant difference compared to the formulations at the  
ambient conditions by ANOVA one-way. C & D: capsules & device) 
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Figure 4.13b A graph showing the relationship between the recovered dose and the  
Nanolac formulations at the different environmental conditions. (Mean ± SD, n=3)(  
*P<0.05, ** P<0.01: significant difference compared to the formulations at the  
ambient conditions by ANOVA one-way. C & D: capsules & device) 
 
ase 
tion. The storage of 
e 0.5% w/w MgSt formulation at both elevated conditions did not alter their emitted dose 
significantly, compared to the same formulation stored at the ambient conditions. The 
emitted dose of the 1.0% w/w MgSt formulation upon storage at 40°C, 75%RH was 
significantly reduced (ANOVA p<0.01) compared to the emitted dose of the same 
formulation stored at ambient conditions. However, upon storage of the formulation at 25°C, 
As shown in Figure 4.14a the environmental conditions did not significantly affect the 
emitted dose of the Lactochem control formulations. Upon storage of the 0.25% w/w MgSt 
formulation at both elevated conditions their emitted doses were significantly reduced 
(ANOVA p<0.01) compared to the same formulation stored at 25°C, 44%RH. The decre
is in accordance with the decrease in the recovered dose of the formula
th
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75%RH no significant difference in the emitted dose compared to the emitted dose of the 
formulation stored at the ambient conditions was observed. These data suggest that only the 
40°C, 75%RH conditions affects the emitted dose of the 1.0% MgSt formulation and that at 
25°C, 75%RH the emitted dose is not affected. 
 
Interestingly, the emitted doses of the all the formulations of Nanolac containing MgSt 
shown in Figure 4.14b, were not significantly affected upon storage at elevated 
environmental conditions when compared to the formulations stored at ambient conditions. 
Interestingly, the emitted dose of the Nanolac control formulation upon storage at 40°C, 
75%RH was significantly lower (ANOVA p<0.01) than the emitted dose of the formulation 
stored at ambient conditions, while the emitted dose of the formulation stored at 25°C, 
75%RH was not significantly different. 
 


























Figure 4.14a A graph showing the relationship between the emitted dose and the  




*P<0.05, ** P<0.01: significant difference compared to the formulations at the  
ambient conditions by ANOVA one-way. C & D: capsules & device) 
 129






























Figure 4.14b A graph showing the relationship between the emitted dose and the  
Nanolac formulations at the different environmental conditions. (Mean ± SD, n=3,  
*P<0.05, ** P<0.01: significant difference compared to the formulations at the  
ambient conditions by ANOVA one-way. C & D: capsules & device) 
 
Upon storage of the Lactochem control formulations at elevated environmental conditions 
the fine particle dose was significantly reduced (ANOVA p<0.05) to approximately half the 
value of the formulation stored at the ambient conditions as shown in figure 4.15a. A 
similar decrease was observed upon storage of the formulation at 25°C, 75%RH, which 
was further decreased by 15% upon storage of the formulation at 40°C, 75%RH. The FPD 
at both elevated conditions was significantly reduced (ANOVA p<0.01) indicating the 
nd 
40°C, 75%RH were significantly reduced by 26% and 59% respectively (ANOVA p<0.01), 
i
major influence the environmental conditions has on the stability performance of the 
formulation. The FPD of the 0.25% w/w MgSt formulations stored at 25°C, 75%RH a
indicat ng the instability of the formulation at elevated conditions of temperature and 
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humidity. However, storage of the 0.5% w/w MgSt formulation at both elevated conditions, 
did not significantly affect the aerosolisation performance. Furthermore, upon storage of 
the 1.0% w/w MgSt formulation at 25°C, 75%RH no significant difference in FPD was 
observed. However, upon storage at 40°C, 75%RH, the FPD was significantly reduced 
(ANOVA p<0.01) indicating that its instability is dependant on the conditions of storage. 
 As shown in Figure 4.15b for the Nanolac formulations, the addition of 0.5% w/w MgSt 
showed the optimum stability in the fine particle dose delivery. The FPD of the 0.25% w/w 
MgSt formulations stored at 25°C, 75%RH and 40°C, 75%RH were significantly reduced 
by 26% and 59% respectively (ANOVA p<0.01). While storage of the 1.0% w/w MgSt 
formulation at 25°C, 75%RH did not significantly affect performance, storage of the 
formulation at 40°C, 75%RH resulted in the FPD being significantly reduced by 65% 
(ANOVA p<0.01). 



































Figure 4.15a A graph showing the relationship between the fine particle dose and th
Lactochem formulations at the different environmental conditions. (Mean ± SD,  
n=3)( 
e  
*P<0.05, ** P<0.01: significant difference compared to the formulations at the  
ambient conditions by ANOVA one-way. C & D: capsules & device) 
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Figure 4.15b A graph showing the relationship between the fine particle dose and the  
Nanolac formulations at the different environmental conditions. (Mean ± SD, n=3)   
( *P<0.05, ** P<0.01: significant difference compared to the formulations at the  
ambient conditions by ANOVA one-way. C & D: capsules & device)  
 
As shown in Figure 4.16a all the formulations except the 0.5% w/w MgSt formulation 
showed a decreased aerosolisation performance upon storage for 3 months at elevated 
environmental conditions. A considerable 11.2% decrease in FPF was observed with the 
control formulation upon storage at 25°C, 75%RH and 40°C, 75%RH, which was further 
reduced by 1.6% upon storage at 40°C, 75%RH. The FPF values of the control 
formulations which were stored at high humidity were significantly lower (ANOVA 
 
ge at 
the same formulation being stored at 40°C, 75%RH (ANOVA p<0.01). This concentration 
p<0.05) compared to the control formulation stored at 25°C, 44%RH. Furthermore, a 6.2%
decrease in the FPF was observed with the 0.25% w/w MgSt formulation upon stora
25°C, 75%RH, having a significantly lower FPF value (ANOVA p<0.05) than the same 
formulation stored at 25°C, 44%RH.  A significant reduction of 16.7% was observed with 
 132
of MgSt gave the best aerosolisation performance but failed to protect the formulation upon 
storage at elevated environmental conditions.   
 
However, the addition of 0.5% w/w MgSt formulation showed a 2.6% increase in the FPF 
upon storage at 25°C, 75%RH, with a further 5.3% increase in the FPF upon storage at 
40°C, 75%RH, with the later formulation being significantly higher (ANOVA p<0.05) than 
the formulation stored at 25°C, 44%RH . It could be suggested that by the addition of 0.5% 
w/w of MgSt to the formulation, resulted in providing stability to the formulation, thus 
being the optimum concentration. The reason could be the sufficient build up of a 
hydrophobic layer of MgSt over the excipient surface of the excipient, protecting it from 
moisture. While the storage of a 1.0% w/w MgSt formulation at 25°C, 75%RH increased 
the FPF, a significant decrease was observed upon storage of the formulation at 40°C, 
75%RH (ANOVA p<0.01). 
 





except the 0.5% w/w MgSt formulation were reduced upon storage at the elevated 
environmental conditions. These data supported the findings for Lactochem formulation
In the control formulation there was a significant decrease upon storage (ANOVA 
















Lactochem 0.25%MgSt 0.5%MgSt 1.0%MgSt
Fi
ne
   
   










































aph showing the relationship between the fine particle fraction of  
covered dose and the Lactochem formulations at the different environmental  




Figure 4.16a A gr
re
*P<0.05, **c P<0.01: significant difference compared to  

























   
   



























Figure 4.16b A graph showing the relationship between the fine particle fraction of  
recovered dose and the Nanolac formulations at the different environmental  
conditions. (Mean ± SD, n=3, *P<0.05, ** P<0.01: significant difference compared to  
lations at the ambient conditions by ANOVA one-way. C & D: capsules &
r
I 
ion, the drop in FPD may relate to the need for a higher deaggregation energy to 
etach drug particles from the carrier surfaces and thus reflects the increase in adhesion 
force acting between attached particles12. Furthermore, the FPD responsible for the 
pharmacological effect might decline because de-agglomeration properties of the powder 
blend will change upon storage due to moisture uptake. Moisture uptake can affect the 
flowability of the powders and the force to detach  micronized particles from the carrier 
surface6.The relationship between increased humidity and decreased aerosolization 
performance of budesonide is most likely due to the condensation of water vapour between 
the formu   
device) 
 
These data suggest that RH and temperatu e play a dominant role on the adhesion 




the contacting surfaces at a specific humidity until it forms an equilibrium with the 
surrounding environment13.The presence of the water leads to the possible formation of a 
meniscus contact leading to a capillary force, thereby increasing the interparticulate forces 
while decreasing the aerosolisation efficiency13.The SEMs and optical images suggest a 
high degree of powder agglomeration. This considerable degree of powder clustering 
(agglomeration) observed for both types of formulations may be an indication of a 
considerable increase in inter-particle adhesion due to capillary interaction, arising from the 
condensation of the increasingly adsorbed water vapour layers onto the surface at high RH 
levels, promoting the formation of a capillary based meniscus around the contact points of 
contiguous surfaces14. The condensation of water vapour on the particles is mainly due to 
the high surface energy of fine particles. If enough water condensation occurs, a liquid 
bridge may form between neighbouring particles, which may greatly increase the attractive 




Bonding due to adsorbed layer interaction will increasingly occur as the humidity 
r at the peaks of roughness in the Lactochem 





The negative Laplace pressure acting across the meniscus and the surface tensional forc
the liquid/air interface induces an attractive force between the contiguous surfac
increases, until at the critical humidity liquid bridge bonding becomes dominant13. 
Furthermore, surface roughness strongly affects bonding due to adsorbed layers. Some 
attraction between adsorbed layers may occu
for
negligible13.Particle agglomeration in a dry pharmaceutical system occurs when attr
interparticle bonding forces are sufficient between individual particles to regroup them15. 
Fine cohesive particles adhere to each other under the influence of electrostatic, van der 
Waals or capillary forces, to form agglomerates that are responsible for their asymmetric
distribution in the mixture16,17. Dry powder agglomeration mechanisms for multi-
component mixtures are not well understood and only a few studies have been conducted 
describing this phenomenon15. Kaye has stated that the more the powder is tumbled arou
with a stearate, the larger are the spontaneously formed agglomerates17.Studies have show
that agglomerates are more easily detached from a carrier surface than single drug 
particles18.This hypothesis could possibly correlate with the behaviour of the 0.5 w/w MgSt 
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formulations which had the greatest aerosol performance. It has been shown by seve
studies that larger particles (up to a certain limit) are more easily detached from a surface 
than smaller ones because whilst adhesion forces increase proportional to particle diameter,
the drag and lift forces exerted by an air stream increase proportional to particle diameter
squared. Therefore, upon aerosolisation the agglomerates are detached from the carrier
surface and remain in the capsules or device due to their large size4. The size of the 
agglomerates and their weight growth are stabilized when a critical size is reached where 
agglomerates start to break up because the attracting forces become equal to or weaker than
gravitational and inertial forces acting on them15. 
 
Another possible explanation for the instability of the formulations could be the presenc
amorphous domains on the surface of a micronized powder which are liable to undergo re-







 levels, due to mobility of these domains 







particle fusion9,10,20,21. As changes in the crystalline nature of a solid result in different 
physical properties, the sluggish transformation during storage can cause unexpected 
problems in processability of the powder22. Moisture is present as liquid bridges at 
humidities. Therefore, increasing the relative humidity leads to increased force of a
between the drug particles and carrier surface, forming agglomerates in some cases whi
remain in the capsule and device upon aerosolisation due to the high energy required to 
detach them. These results indicate that interparticulate interactions increased during 
storage at elevated environmental conditions. Thus, water sorption on the particle surface 
may increase the attractive forces between particles through capillary forces14,23,1,24. The 
decrease in the fine particle fraction was more profound in the Lactochem formulations. 
This could be due to the presence of lactose fines which may exacerbate the instability of 
carrier based formulations when subjected to environmental conditions of elevate
temperature and relative humidity. The reason for this phenomenon could be the potential 
increase in the overall surface area available for water vapour adsorption. In addition, as a 
result of the high energy processing of the fine carrier particulates, they are also more 
likely to show evidence of crystalline disorder, demonstrating a proportion of amor
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regions that would further enhance solid crystal bridging due to re-crystallisation at 
conditions of elevated temperature and relative humidity2. 
 
Treatment of particle surfaces by hydrophobic compounds such as MgSt helps to make the
powder less sensitive to ambient moisture12. The effect of coating was demonstrated by 
Hickey et al (1990) 25 who used fatty acids to get an effective coating that was able to
inhibit hygroscopic particle growth of a model drug powder. This coating modifies particle














protective barrier to external water vapour condensing on the powder formulation. This was 
A
governing particle-particle and particle-surface interactions.  Relative humidity affects the 
interparticulate forces by reducing the electrostatic forces and inducing capillary forces. At 
low RH, the water vapour condensation on the particles is negligible and therefore by
increasing the RH results in a reduction of the interparticulate forces by decreasing 
electrostatic forces, as a result of improving electrical charge decay5. However at high
the water uptake by the particle is substantial and therefore by increasing the RH woul
increase interparticulate forces as a result of capillary forces5. 
 
Looking at the data from this Chapter, it could be suggested that under the elevated 
environmental conditions, the interparticulate forces between the drug particles are 
increased due to capillary forces, resulting in poorer entrainment of the particles into a
inhaled air stream and leading to a decreased emitted dose from the inhaler. After 
entrainment, the drag forces of the inhaled air stream were probably not sufficient to 
deaggregate the particle agglomerates and hence the fine particle fraction was reduced. In
addition,  due to the fact that the water vapour was allowed to condense on particle surface
for a prolonged period of time, and especially at elevated temperatures, it could be t
did not only increase the interparticulate forces but also induced growth of drug particles 
due to migration of adsorbed water molecules into those particles. Both effects will reduce 
the delivery efficiency of the drug as explained by Jashnani et al (1995) 6. The addition
MgSt was expected to reduce the rate of increase in RH inside the capsule by providing a 
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only achieved by the addition of 0.5% w/w MgSt which may be sufficient to form a 
sufficient hydrophobic layer over the excipient surface and thus protecting it from de-
abilising and also preventing the development of stronger binding between the particles 
ase in the performance upon storage 
t conditions of elevated temperature and relative humidity, the potential for caking and 
es of the 
ility 
 
anolac and Lactochem 







therefore facilitating their detachment. 
 
4.4.5 Optical imaging of powder samples 
 
To further probe the potential explanation for the decre
a
agglomeration of the formulations was examined via optical imaging. Optical imag
blends released from the capsules stored for three months at 25°C, 75%RH and 40°C, 
75%RH are shown in figures 4.10 to 4.11.  The optical images may verify the possible 
mechanism of failure of the carrier based formulation upon exposure to accelerate stab
conditions, previously suggested with the electron microgrpahs.  The images of 
formulations carefully release from the capsules showed that under high relative humidity 
and temperature, the formulations underwent a considerable degree of powder clustering
and agglomeration. Agglomeration was observed for both the N
fo
agglomeration with the Lactochem formulations and in some cases all the powder bl
formed a single pellet, as shown in figure 4.10, Image D. The tendency for powder c
may be associated with the instability of intrinsic fine lactose material, particularly when
subjected to high temperature and relative humidity. Moreover, this could possibly
occurring due to the potential increase in the overall surface area available for water v
adsorption. Therefore, due to their high energy processing of fine carrier particulates, they 
are more likely to show evidence of crystalline disorder, demonstrating a proportion of 
amorphous regions that would further enhance solid crystal bridging due to re-
crystallisation at elevated environmental conditions.  
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%RH and B) 
at 40°C, 75%RH, C) 0.25%w/w MgSt+Lactochem+budesonide at 25°C,75%RH and D) 
at 40°C,75%RH, E) 0.5%w/w MgSt+Lactochem+budesonide at 25°C,75%RH and F) at 
40°C,75%RH, G) 1.0%w/w MgSt+Lactochem+budesonide at 25°C,75%RH and H) at 
40°C,75%RH. 
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Figure 4.18 Optical images of A) Nanolac and budesonide at 25°C, 75%RH and B) at 
40°C, 75%RH, C) 0.25%w/w MgSt+Nanolac +budesonide at 25°C,75%RH and D) at 
40°C,75%RH, E) 0.5%w/w MgSt+Nanolac +budesonide at 25°C,75%RH and F) at 





The variation in temperature and relative humidity levels of the environment of a typical 
carrier based DPI formulation was found to influence the aerosol delivery performance. 
This study suggested that capillary interactions influence DPI performance. As humidity 
increases, capillary forces become a dominating factor because of the multilayer sorption of 
ater onto crystal surfaces. Ultimately, this increase in energy will influence the 
aerosolisation performance of the DPI formulation. Furthermore significant differences in 
aerosolisation efficiency at elevated humidities may be attributed to variations in surface 
stability.  The relationship between humidity and aerosolisation performance can be 
attributed to the balance of interparticulate forces acting between the individual 
particulates, the proportion of each being related to the physical and chemical properties of 
e material. The addition of 0.5% w/w Mg o both types of formulations provided a 
protective coating which kept it stable under the high RH and temperature which it was 
subjected and even increased its aerosolisation performance suggesting that 0.5% w/w of 
MgSt is the optimum concentration for maintaining a formulation stable at elevated 
humidity and temperature.  Insufficient detachment and deaggregation of drug particles on 
inhalation is a major reason for the ineffective delivery of drugs to the lungs. These factors 
have to be carefully balanced so as to ensure dose uniformity and delivery efficiency of 
rugs from dry powder inhaler formulations.  
 
This study has clearly emphasized the need to understand long term stability issues in order 
to achieve and maintain aerosolisation performance. Clearly, since an increase in adhesion 
energy will reduce the dispersion and deaggregation properties of a DPI formulation, the 
environmental conditions during processing, packaging and storage will ultimately 
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Chapter 5  
Influence of carrier lactose particles modifications 
dry powder inhalers performance directly on 
monitored by in line optical measurements 
.1 Introduction 
5.1.1 Laser diffraction 
 
aser diffraction techniques, may become a powerful tool in the rapid development and 
testing of inhalation devices and their formulations. The technique is fast, reliable and the 
eories of light diffraction are well described1. Particle sizing by laser diffraction works on 
the principle that small particles in the path of a monochromatic light beam scatter the light 
 a characteristic, symmetrical pattern onto a Fourier lens, and their intensities measured 
by a photodetector array. With the use of an inversion algorithm, a particle size distribution 
 inferred from the collected diffracted light data2. This technique is widely used for 
particle size analysis, and there are several commercial instruments based on the principle 
f laser light diffraction in determining particle sizes distributions3.A schematic diagram of 











      Figure 5.1 A diagram showing the principle of the laser light diffraction. 
owever, laser diffraction does have limitations. It exhibits poor inter-instrument 
reproducibility, it offers limited resolution and gives information of limited value for 
4.  
A major advantage of the approach is that it can analyse a large number of classes in over a 
wide size range which is important in lung deposition. Laser diffraction was first 
introduced for analysing the output of nebulisers in the 1990’s1. This technique was used 
for nebulisers because they generate aerosols over a long period of time (5 to 30 minutes). 
The size distribution for aqueous droplets obtained with laser diffraction were shown not to 
differ significantly from aerodynamic size distribution5,6,7,8. However, the problem in testing 
 
H
submicrometre particles which leads to inaccurate data4. The analyser-to-analyser 
reproducibility is determined by how accurately the laser can be aligned and measurement 
reproducibility by how consistently the alignment can be maintained. If the laser is not 
accurately aligned, the light scatter pattern will be observed at the incorrect angle, and 
hence lead to errors in particle sizing measurements4.The resolution is the ability of the 
system to differentiate between similarly sized particles in order to get measurements of the 
correct shape and width of the particle size distribution and to determine any tails or 
shoulders. It is determined by how well the angular scattering pattern is measured. This 
problem can be addressed by covering a wide angular range with a sufficient number of 
detectors, so that information from the scattered light is not lost
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aqueous aerosol particles was what diffraction theory to use (Mie or Fraunhofer) and how 
to replicate the inspiratory flow rate through the inhaler9. The application of in line laser 
diffraction for carrier based DPI evaluation or development has not been extensively 
investigated. The major argument is the fact that the aerosol from a DPI is a mixture of 
primary particles and small agglomerates, for which the dynamic shape factor and density 
vary from particle to particle and so an aerodynamic size distribution can not be calculated 
from the laser diffraction result1. However, aerodynamic size distribution is only important 
for predicting lung deposition. The objective of a DPI development is to get the size 
istribution of the aerosol from the DPI as close as possible to the size distribution of the 





dose and under inspiratory conditions.  
 
5.1.2 VariDose device  
 
Varidose is a new optical instrument, developed by Loughborough University, which may 
speed up the measurement of drug inhaler performance, therefore reducing the amount o
time the pharmaceutical industry spends in research and development and during qualit
control measurement of formulations. It utilises custom-designed and state of the art 
optoelectronics and takes less than 60 seconds to run each test. It could be a potential 
breakthrough for the pharmaceutical industry as it enables quick and efficient testing 
wide range of drug-device combinations, without relying on standard inhaler testing 








Figure 5.2 Images of the A) VariDose device with the sensor rings and B) the Varidose 
tube intersected by co-planar beams of blue and infrared light. 






omponent of a collimated light beam I, after traversing a homogeneous scattering medium 
of thickness L, is estimated by the equation: 
 
   Equation 5.1                  I= I0 exp(-μtrL) 
 




passes through a tube intersected by co-planar beams of red, blue and infra-red light. As the
light passes through, in-built sensors monitor the structure of the evolving cloud. The 
analysis is then presented on a standard PC. The varidose provides valuable information o
the detailed characteristics of the particle or droplet cloud emitted by the inhaler and c
also be positioned in-line with other measurement devices or a patient. 
The results can be used to investigate essential cloud characteristics related to variability in
particle size distribution, fine particle fraction and dose to pin-point how design 
modifications could improve both drug and device effectiveness
c
The absorption coefficient μa, the scattering coeffici μs and the anisotropy factor g 
depend on the optical and geometrical properties of the particles and on the wavelength of 
the light. The scattering anisotropy g, is calculated as the mean cosine of the scattering 
angle. Depending upon the conditions of the medium, this value can vary from g = 1 
(forward scattering), through g =0 (isotropic scattering) to g = -1 (back scattering). An 
estimate of the reduced scattering coefficient μs (1-g) for the drug cloud can be made by 
means of a particle scattering model and this model will dominate the absorption 
coefficient (in the wavelength of interest: 450-850 nm), hereafter assumed to be zero10. 
Assuming that particles scatter light independently the scattering coefficient of many 




Equation 5.2                                   μs = Nσs 
 
Where N is the number of scattering particles per unit volume and σs is the scattering cross-
sectional area of a single particle. 
For mono-dispersions, the particle number is the ratio of the particle volume concentration 
Cv and the single-particle volume (assumed to be spherical): 
 




CN vπ=                                                                     
Where D is the particle diameter. Using equation 5.3, the transport scattering atten







σμ −=Equation 5.4                                                                                       
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The scattering cross-section is sometimes expressed in terms of the product between a 
geometric cross-section (again assumed spherical) and a scattering efficiency factor Q, in
which case: 
 





)1(3 −=μ                                                         
The scattering cross section and the anisotropy factor for spheres were calculated by m
of Mie scattering theory.                                                            
 
eans 
ics of the cloud, not only in terms of its density, but 
also in terms of its homogeneity. In making the hypothesis that the distribution of particles 
lso implied that the degree of inhomogeneity 
ill characterise the efficiency of actuation, formulation and device performance. One way 
quence of the dissociation and entrainment 
ed as part of this study. 
5.1.3 Basic components of a Varidose 
The essential components of the varidose are shown in figure 5.2. The airflow can be 
er device creating the aerosol cloud. The cloud then propagates 
rough a glass tube and the sensor module makes measurements at a given distance from 
the inhaler’s mouthpiece. All connections in the flow path are airtight and the tube is 
ated ligh bre 
collimator Ocean Optics tungsten halogen light source (bulb colour temperature 3,100 °K). 
The SELFOC® fibre collimator is comprised of a 0.25 pitch GRIN lens and a 200μm fibre 
with numerical aperture of 0.50 and beam divergence angle of 6.5°. The same fibre 
The varidose is sensitive to the dynam
in the drug cloud is not homogeneous, it is a
w
in which the cloud might be inhomogeneous is in terms of the spatial distribution of 
particle size and this might be a conse
10mechanism of cloud formation . A simultaneous analysis of the delivered dose using light 
obscuration (Varidose) and a twin stage impinger (TSI) was perform
 
 
provided either by a patient, a breathing simulating machine or a vacuum pump. The 
airflow actuates an inhal
th
screened from the ambient light. The collim t beam is formed by a SELFOC® fi
 151
collimator is used for collecting the light passing through the cloud. An Ocean Optics fibre 




Figure 5.3 Schematic diagram for optical characterization of the pulmonary drug 
delivery. 
 
5.1.4 Sensor position 
 
The position of the sensor down the stream of propagation produces a profound influence 
on the aerosol sample that has been actually measured. For instance, if the sensors were 
 the measurement would characterize particles in 
ediate vicinity of the inhaler. The sensor records an accumulative effect of 
ple, 
intensities of the illuminating and collected light . The residue of fine particles can be 
adjacent to the mouthpiece of the inhaler
the imm
temporal and spatial variations in the cloud. The right position for the sensors depends on 
the individual experiment requirements and the purpose of the measurements. For exam
multiple sensors aligned on the cloud path would provide information on the cloud 
development. For pulmonary delivery, the aim is to characterize the cloud that is emitted 
from the device. Therefore, in this case the cloud in the middle of the mouth represents a 
viable sample of the particles which would be available for deep lung deposition11. 
 
Particles moving along the glass tube interact with the tube walls resulting in the constant 
contamination of the tube walls with particle sediment. The wall sediment affects the 
11
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taken into account by the data analysis and may even contribute to the aerosol cloud 
characterization. 
 
5.1.5 Data acquisition 
 
The varidose measures the light intensity as a function of time. A light detector provides a 
signal that is proportional to the number of photons accumulated by the detector during the 
measurement period. The measurement period is a time period and is often referred to as 
the integration time for the detection system. The detector’s readings are streamed to 
omputer memory with the time stamps, using an appropriate integration time. A computer 
n time are the main variable parameters which control the accuracy and efficacy 





bscuration at a given wavelength. Varidose provides a spectrum of transmitted light 
f the 
c






As an aerosol cloud is released from an inhaler device it possesses characteristics such as
volume, the start and the end of the cloud release, particle properties and the propagation 
velocity. The cloud volume and geometric dimensions of the passage define the clou
length, which can be expressed in units of time or length. A single optical sensor records 
the light intensity as a function of time; therefore each actuation is characterized by a 
temporal profile of light intensity. 
 
5.1.7 Data analysis 
The analysis of the varidose measurements relate the aerosol content and the ligh  
o
intensity for every 5 milliseconds. The profile can be characterized by the position of the 
maximum (the peak position), the maximal value (the peak value) and the full width o
half maximum11 (FWHM). 
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5.2 Aims of the study 
 
The in-vitro deposition characteristics of aerosol based formulations requires significant 
terms of personnel and analytical equipment. Furthermore, due to 
itation in automation it is a highly time consuming exercise. There is therefore an 
-throughput aerodynamic classifier which can 
 for testing aerosol based systems for design, cycling, manufacturing and 
therapeutic management.  
ore precisely, this study was performed in order to evaluate the use of the Varidose 
 
ch 
ments but further tests need to be carried out. 
ail 
 
amount of resources, in 
its lim
ever increasing need to develop a high
rapidly test the performance and predict the variability in the delivery characteristics of 
both nasal and inhalation based formulations. 
 
This study will investigate the use of a novel in-line optical sensing technology for 
actuation-by-actuation assessment and to utilise the system to investigate the 
physicochemical properties which govern the aerosol delivery of inhalation systems. The 




device as a potential screening tool. The pharmaceutical devices currently available for the
characterisation of drug formulations like the NGI, TSI, MSLI are labour intensive, 
therefore costing a lot of money and time to pharmaceutical companies12. A device whi
would characterise the drug formulations and give the information required in a shorter 
period of time, would be of benefit to pharmaceutical companies. The Varidose could 
potentially meet up to these require
 
5.3 Methods 
General methods of each technique or apparatus used in this study are described in det




5.3.1 Preparation of Magnesium stearate-lactose blend 





 minute. Approximately 3.9416g of the 
agnesium stearate – lactose blend was accurately weighed.  




tus, Loughborough, UK) and more lactose was added in 




 performed using Varidose and a Twin Stage Impinger (TSI) in tandem 
(Copley Scientific Apparatus, Nottingham, UK). The Varidose sensor-rings were placed 
cal axes was set at 19mm. The varidose was connected to a laptop which had 
e varidose Software V3.5. The distance between the mouthpiece of the inhaler and the 
rst sensor ring was 25 mm. The settings on the software were: trigger channel 1, 
B
magnesium stearate were prepared under high shear. Half the amount of lactose requir
for the blend was accurately weighed and then the amount of magnesium stearate whic
was accurately weighed was placed in the lactose. The other half remaining amount
lactose was subsequently weighed so as to have the total mass required and sandw
between the magnesium stearate layer. The blend was mixed in the high shear mixer, 
KSM2 (Brown, Kronberg, Germany) for 1
m
 
Budesonide was subsequently blended geometrically with the MgSt-lactos
plastic vial. An amount of the blend (~0.12g), equivalent to about twice the total mass o
budesonide being used for the blend was put in the plastic vial and then the am
budesonide was added (0.0584g). This was then mixed for 1 minute using a Whirlimix
(Fisons Scientific Appara
g
addition. This was done until all the lactose (3.9416g) was added to the vial. The blend was 
then mixed in a turbula mixer (Turbula, Glen Creston Ltd, Stanmore, UK) at 46 revolutions
per minute for thirty minutes. The formulation was then placed in a jar that was
sealed and allowed to stand for 48 hours. Drug content uniformity of the formulation wa
carried out as described in Chapter 2. 
 
5.3.2 Varidose experimental set up 
 
The analysis was





experiment time 2000msec and time out 10000msec. A photograph of the experimental set-




                     Figure 5.4 An image of the Varidose-TSI experimental set up. 
 
5.3.3 In vitro aerosolisation studies 
1) Experimental set-up  
 
The TSI contained 30 ml of mobile phase in stage 2 and 7 ml in stage 1, which at 60 L/min 
dynamic diameter of 6.4 μm between the two stages. 






produced a cut-off mass median aero
F
settings were: trigger channel 1, experiment time 2000msec and time out 10000msec.T
Rotahaler (GlaxoWellcome, UK) was primed by loading a filled capsule (33 ± 4 m
containing the formulation (budesonide and lactose pre-conditioned with 1% w/w MgS
into the inhaler and twisting to separate the upper and lower sections exposing the 
formulations to an airstream passing through the device. The inhaler was attached to t
cylindrical glass tube of the Varidose via a rubber mouthpiece adaptor. Upon comp
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the capsule firing, the TSI apparatus was then dismantled and each stage was washed with
mobile phase into 100ml volumetric flasks. This procedure w
 
as carried out until 20 
ctuations had been conducted. The concentration of the drug was then determined using 
e HPLC method.  
 
2) Addition of a pre-separator to the Varidose setup 
 
A pre-separator was also added between the USP induction port and the Varidose sensor 
unit, followed by the TSI without the throat piece, in order to prevent oversized particles 
from depositing on the glass tube. The Varidose sensor unit was placed in a vertical 
orientation to the air flow. The pre-separator incorporates two collection surfaces working 
in tandem. The first (scalper) collection surface is a circular cup, containing 15ml of mobile 
phase, beneath the inlet of the pre-separator and is intended to remove very large particles 
like lactose carrier particles. The mobile phase is added to reduce particle re-entrainment 
from the cup. The scalper is followed by the second collection surface, which has a much 
cut size of 
e first stage of the impactor itself, while not removing particles that are of a size to be 
captured on the second impactor stage. 
e in vitro testing of the formulations containing 
hese formulations a large amount of fines was present, and 
erefore a pre-separator was used to capture most of the large particles enabling only the 
a
th
sharper cut than the scalper to eliminate most particles that are larger than the 
th
The pre-separator was required, for th
extrinsic lactose fines. In t
th
small drug particles to pass through it and continue through the varidose device. 
 
5.3.3.1 Preparation of carrier based formulations containing fines 
 
Ten percent of Sorbolac 400 (fines of lactose) was geometrically blended with the 
untreated (Lactochem) and surface etched lactose (Nanolac) in a ratio 1:67.5 w/w % using 
the same procedure mentioned above. Briefly, 3.604g of the carrier was weighed out and 
0.40024g of Sorbolac 400 and were mixed together by geometric mixing using a 
Whirlymixer (Fisons Scientific Equipment, Loughborough, UK) for 60 seconds. Upon 
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completion of the geometric mixing, the blend was placed in a Turbula (Bachofen, Basel, 
Switzerland) and blended at 46 rev/min for 30 minutes. Then, 3.9743g of this blend was 
weighed out and geometrically mixed with 0.0257g of budesonide according to the 
procedure mentioned above. Blends were stored in a tightly sealed container with a 
turated salt solution of potassium carbonate, which produced a relative humidity of 44% 





RH at 25°C. Hard HPMC capsules were filled with 25 ±
 
 
5.4 Results and Discussion 
5.4.1 Scanning electron microscopy 
 
To examine the relative distribution of the drug particles on the surface of the lactose
carrier, scanning electron microscopy was used. Figure 5.7 shows electron micrographs 
the surface topography of the blend containing budesonide and lactose, in a 1:67.5 ratio
together with 1%w/w MgSt.   
                                                                      
          
A) B) 
Figure 5.5 Representative scanning micrographs of blend containing budesonide and 




5.4.2 In vitro aerosolization studies 
 
Figure 5.6 shows the variation of the light obscuration for 9 consecutive actuations f
Rotahaler DPI device. There is no noticeable repeated pattern in these actuations, wh
indicative of high dose-by-dose variability. Each actuation has been simultaneously 




bsequent rings was approximately 4mm. Each ring contains three azimuth sensors (120° 





























Figure 5.6 A graph showing the light obscuration values for each actuation estimated 
by the varidose apparatus. 
 
The three profiles from the same ring are used to present the 3D visualisation of the optical 
bscuration profile is characterised by the same parameter. To evaluate the variations in the 
density of the cloud. The 3D visualisations from the sequent rings indicate the evolution of 
the cloud during propagation. To describe the cloud evolution in comparative terms, each 
o
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light obscuration data from the varidose, the corresponding fine particle delivery of each 
ot was measured via the twin stage impinger (TSI).  The fine particle dose for the nine sh
shots are shown in Figure 5.7. From these data, there is a suggestion that the light 
obscuration measured with the Varidose strongly correlates with the fine particle dose 
(FPD) measurements. This agreement is more clearly represented in Figure 5.8. 
Sequence of runs





















Figure 5.7 A graph showing the FPD for each actuation calculated with the TSI. 


























Figure 5.8 The correlation graph showing the relationship between the FPD estimated 
by the Varidose and calculated by the TSI. 
 
As shown, there is a high variability between each actuation in the dose being delivered
the respiratory tract. The observed large variation is consistent with typical dose 
 to 
variations 
delivered by the Rotahaler DPI device. Furthermore, this variability in the dose shown with 
the data calculated from the TSI was also observed with the data from the varidose. As 
shown in Figure 5.8 the TSI data correlates with the data from the varidose; where the fine 
particle dose was high, the light obscuration was also high and where the fine particle dose 
was low, the light obscuration was also low. However, there was a noticeable difference 
between actuations 4 and 5. Actuation 4 had the higher light obscuration as can be seen in 
figure 5.7 and actuation 7 has the lowest light obscuration. However, actuation 5 has the 
higher fine particle dose from the TSI measurements. For low doses, the shot by shot 
measurements correlated well. This rapid means of testing formulations and devices is 
critically important for testing inhalation systems. 
Upon construction of the correlation graph a straight line was observed with R2= 0.8476. 
There is good correlation between low dose delivery and the light obscuration, but there 
might be some issue with the higher concentrations which may be in relation to the 
sat e 
varidose may provide a semi-empirical means of characterising the aerosol cloud 
produced via an inhalation device and a sensitive means of determining dose-by-dose 
fluctuations.  
  
The main purpose for using the varidose is to have an estimation of the fine particle dose of 
a formulation. However, in the presence of significant amount on intrinsic and extrinsic 
fine excipient material evaluating the dose variability of the drug may be too difficult. To 
evaluate the influence of fine lactose particles on the varidose response, formulations 
containing 10%w/w fines were tested. To limit the issues relating to high obscuration, a 
pre-separator was attached to the end of the throat section of the impinger to remove coarse 
particles.  
 
uration issues with respect to the obscuration. Nevertheless, these data suggest that th
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The experiment was performed in the same set up as above with the exception of a pre-
separator. The addition of a pre-separator should increase the varidose sensitivity to the 
ariation of the drug dose. If the TSI data correlated with the varidose data then the 
at 
v
varidose could be used for the investigation of complex powder mixtures. 
 
As shown in figures 5.9, 5.10 and 5.11, 5.12 the peak obscuration data from the varidose 
did not correlate with the fine particle dose data from the TSI. The varidose data show th
all actuations were characterised with a low peak value and a high residue value. In 
addition, the Nanolac formulation had slightly lower peak obscuration values compared to 
the lactochem formulation and this could be due to lower amounts of fines scattering the 
light. It is hard to make any definite conclusions from these data due to the low level of 
obscuration. While it could be possible that the position of the varidose sensors was not 
optimal for the purpose of the dose evaluation, it is more likely that the co-removal of 
extrinsic fines during aerolisation masks the determination of the dose variation of the 
























Figure 5.9 A graph showing the light obscuration values for each actuation estimated 




Figure 5.10 A graph showing the FPD for each actuation calculated with the TSI for


























Figure 5.11 A graph showing the light obscuration values for each actuation estimated 
by the Varidose for the formulation containing Nanolac+10%fines+budesonide. 
 
Sequence of runs
















































Figure 5.12 A graph showing the FPD for each actuation calculated with the TSI for 
the formulation containing Nanolac+10%fines+budesonide. 
 
A study performed by Kusmartseva et al (2004) 10 utilising the varidose technology showed 
a strong correlation between the varidose measurements and a Bricanyl® Turbohaler® 
with the varidose and the TSI, with a correlation coefficient of 0.94 and p<0.0001 for the 
assessment of variations in fine particle dose.  However, the formulation in this study 
consisted of pure terbutaline sulphate and no excipients, so each actuation contained 500μg 
of terbutaline sulphate. 
 
Two types of drug formulations have been investigated simultaneously in this study using 
the varidose and in vitro testing (TSI). The formulations contained a significant amount of 
excipients: the carrier particles and lactose intrinsic fines. These types of formulations 
seriously challenged the varidose assessment. The in vitro data from the formulations 
containing 1.0% w/w MgSt correlated well with the varidose light obscuration data. 
However, when conducting further studies, the correlation with increasing % obscuration 
was not observed.  
 
 164
Therefore the attempt to classify and identify a formulation with good aerosol deposition 
performance with the varidose at this stage was unsuccessful. Further studies need to be 
conducted adjusting the experimental set-up and the position of the varidose sensors.  
 
5.5 Conclusion 
Pharmaceutical industries are continually investigating easier ways of determining and 
classifying the performance of their formulations that will save time and resource. Laser 
diffraction has been shown to be a valuable tool for comparative inhaler evaluation, device 
development, powder formulation and quality control. The varidose device which is based 
on laser diffraction has the potential of complying to the requirements needed in such a 
system by simply analysing the aerosol cloud generated by the inhaler formulation 
nt 
econds to assess a single 
ose actuation, instead of two hours required for a measurement by a cascade impactor. In 
addition to that, more detailed and also different information about the aerosol cloud is 
h an optimal experimental set-up for different types of 
mulations.  
investigated. The varidose technology has been developed and intended for the assessme
of efficiency of the pulmonary delivery. It requires only a few s
d
obtained. It was also designed to be used as an indicator for how well the drug formulation 
is dispersed during pulmonary delivery and therefore may rapidly measure the delivered 
dose in-line with a patient. However, the attempt to classify and identify different grades of 
formulations of good performance with the varidose at this instance was unsuccessful. The 
main reason for this may relate to the experimental set up. Further studies need to be 
conducted in order to establis
for
 
This study suggested that a relation between the varidose data and the TSI data was nots 
established and at this instance the varidose can not be used as a stand-alone technology for 
evaluating carrier based formulations. The varidose could potentially be used to make 
quick assessment of the performance of a formulation, but further studies need to be 
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pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing) Part I: 















Dry powder inhaler formulations consist of small drug particles (≤5μm) and larger carrier 
rticles. The drug particles are usually blended over the surface of the excipient. Upon 
rosolisation, the drug particles detach from the surface of the excipient and penetrate into 
the lungs. However, in order to achieve this, the adhesive forces that exist between the drug 
d carrier particles have to be overcome in order to aerosolise the drug particles.  One of 
e major challenges in dry powder inhalation is to achieve a controlled balance of the 
forces. 
any strategies have been employed in order to improve the aerosolisation efficiency of 
DPI formulations. These have mainly concentrated on reducing the force of adhesion by 
anipulating the macroscopic properties of the carrier particles. These include particle 
ze1, particle shape2, surface rugosity3 and surface passivation via addition of ternary 
components4. 
A, magnesium stearate (MgSt) and its  
ation efficiency through modification of the interparticulate 
rces. It is clear that the addition of MgSt to a formulation modifies the balance between 
the interparticulate adhesions and the forces acting to overcome them during inhalation, as 
ell as the presence of fines. This study, investigated the relationship between the 
ncentration of MgSt in DPI formulations and their aerosolisation performance. This was 
achieved by using two different types of carriers in the powder formulations, Nanolac and 
ctochem, and changing the concentration of MgSt within them. In addition, these 
rmulations underwent long term stability testing by being stored for 3 months at 25°C, 













This study focuses on the addition of a FC







examine any changes. M
rapid drug screening was
oreover, the VariDose device, which is a new emerging device for 
 investigated for a potential indicator for how well the drug 





eir small surface contact area and therefore only a small amount of energy is 
quired to detach them, making the drug particle detachment easier. In addition, 
ng 
rgy 







In order to improve dry powder inhaler formulation delivery performance, the influence of 
the addition of different concentrations of MgSt to the formulations was investigated. Tw
different types of carriers were used for the preparation of the formulations: Nanolac and 
Lactochem, differing in their surface morphology and therefore the interparticulate forces.  
 
The drug particles and the Lactochem surface have weak forces of adhesion between th
due to th
re
Lactochem contains fines which could occupy the active sites of the carrier, leaving the 
passive sites to be occupied by the drug particles, facilitating their detachment. On the 
other hand, Nanolac has a smooth surface with a very small amount of fines in any, havi
a large surface contact area with the drug particles and therefore a large amount of ene
is required to d
 
With the addition of MgSt, the results showed that the addition of 0.25% w/w MgS
the optimum concentration for the greatest aerosol deposition performance amongst the 
Lactochem formulations, while the 0.5% w/w MgSt was the optimum concentration for the
greatest aerosolisation efficiency amongst the Nanolac formulations. 
 
The influence of the environmental conditions on the aerosolisation performance of these 
formulations was then investigated upon storage for 3 months at different conditions; 
25°C/44%RH, 25°C/75%RH and 40°C/75%RH. Results show that the addition of 0.5
w/w MgSt in DPI formulations is able to stabilise the powder blends against humidity and
temperature. Whereas the controlled formulations which did not contain any MgSt w
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heavily affected by moisture, the applied of 0.5% w/w MgSt helps to make the powder 
blend less susceptible to elevated humidity.  The reason could be the formation of a 
hydrophobic coating by MgSt over the whole surface of the excipient, protecting it from 
oisture. Therefore, powder stability upon storage at high environmental conditions may 
e addition of 0.5% w/w MgSt.  The addition of 0.25% w/w MgSt to the 
Lactochem formulations exhibited the greatest aerosol deposition performance, but 
owever failed to keep this performance upon storage at elevated environmental conditions 








been described by Amass et al (1996) 5 that different types of de- agglomeration forces can 
m
be increased by th
h
for a period of 3 months. On the other hand, the addition of 0.5% w/w MgSt to the Nanolac 
formulations exhibited the greatest aerosolisation performance as well as protecting the 
formulation from de-stabilising at high RH and temperature and even increasing its 
aerosolisation efficiency upon storage. Clearly, the environmental conditions under which a 
fo
seen in the aerosol deposition performance of the DPI formulations. 
 
A new emerging technology for an in-line, real-time assessment of the efficiency 
pulmonary drug delivery was also investigated. The VariDose techology exploits the 
phenomenon of light scattering by small particles. Additionally, the technology investig
how the aerosol cloud changes along the propagation path. The experimental results of the 
first experiment performed show a strong correlation between the VariDose measurements
and the conventional in-vitro data. However, upon further testing of more complex powder 
fo
suggested no correlation between the VariDose measurements and the in-vitro data, failin
to give estimations of the fine particle dose.  
 
6.3 Suggested future work 
The data presented in this thesis and various previous studies clearly demonstrate that the 
interparticulate interactions play a major role in drug deposition performance of DPI 
formulations. However, despite the fact that this factor is quite important, only a very few
studies exist in which improvement of the de-agglomeration efficiency is the objective, 
since most of the studies focus on the control of the adhesive forces in the mixture. It has
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be used but neither the effectiveness of these forces nor the principles to generate these 
forces have been studies thoroughly. Clearly, a better understanding of these de-
agglomeration forces would possibly lead to a greater aerosolisation efficiency of the DPI
formulations.  
 
Moreover, such investigations are more preferably to be conducted concomitantly w
extensive long term stability studies. In addition, extended effort may also be  
undertaken to gain a more valuable insight into the role of fine carrier particulates on 
aerosolisation behaviour and their mechanism of action since it still unclear. The second 
area which would benefit from further study is the relationship between the environm
conditions and formulation performance. A suitable selection of an environmentally-
insensitive salt with reduced hygroscopicity6 that can be added to the formulations in order






cceptable range of temperature and humidity7 should be determined which will enable the 
ry powder inhalation research has been performed since the 1970’s, but the sure thing is 
rch will continue to challenge researchers to develop 
approaches, devices and formulations that will maximize the clinical efficacy and patient 
a
formulation to keep its efficacy over a period of time.  
 
These studies should be repeated using other force control agents like leucine and  
lecithin and examining their effect on the aerosolisation efficiency of DPI formulations to 
determine which FCA can provide the greatest delivery performance. Clearly, the future 
advances in inhalation particle engineering will require a greater understanding of 
interparticulate interactions at the mesoscopic level8and the elucidation of specific 
physicochemical and environmental factors which govern their variability. 
 
D
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